Toxicology

Digoxin and cardiac glycosides

General overview

Digoxin and digitoxin are cardiac glycoside medications traditionally used in the management of several heart conditions. Their therapeutic actions mainly involve modifying cardiac contraction and electrical conduction.

Pharmaceutical forms

Cardiac glycoside preparations have included deslanoside, digoxin, digitoxin, and powdered digitalis. Digoxin has been marketed in products such as Lanoxin and Lanoxicaps, while digitoxin has appeared under several other brand names.

Animal sources

Certain species of Bufo toads contain naturally occurring substances such as bufogins and bufotoxins that produce effects similar to pharmaceutical cardiac glycosides.

Other sources

Cardiac glycoside–like substances have also been identified in some unregulated topical aphrodisiac products. Numerous plants contain similar compounds and can produce comparable toxicity.

Therapeutic uses

Digoxin and digitoxin have been used to control ventricular rate in atrial fibrillation, atrial flutter, and some forms of supraventricular tachycardia.

Use in heart failure

These medications have also been used to support cardiac output in selected patients with congestive heart failure.

Typical digoxin dosing

Historically, adult digoxin therapy could begin with divided loading doses followed by a lower daily maintenance dose. Exact dosing depends on the patient’s condition, kidney function, age, and other clinical factors.

Toxic dose

Serious and potentially fatal poisoning has occurred after ingestion of more than approximately 10 mg of digoxin in adults or more than 4 mg in children.

Cellular mechanism

Digoxin inhibits the sodium-potassium ATPase pump in cardiac cells. This causes intracellular sodium to rise and indirectly increases intracellular calcium, thereby strengthening myocardial contraction.

Effects on cardiac conduction

Digoxin also increases parasympathetic or vagal activity. This slows the heart rate, reduces conduction through the atrioventricular node, and increases the refractory period of the atrioventricular conduction system.

Frequency of poisoning

Exposure to cardiac glycosides is relatively common. Many cases produce mild effects, but unrecognized toxicity can lead to severe dysrhythmias and death.

Common causes

Significant poisoning may occur after intentional overdose, medication errors, excessive therapeutic dosing, or accumulation during chronic treatment.

Exposure in children

In infants, unexplained exposure may raise concern for inappropriate administration or neglect. In older children and adolescents, intentional ingestion should be considered when supported by the circumstances.

Cardiac risk factors

Patients with underlying structural or electrical heart disease may be more susceptible to dangerous dysrhythmias during cardiac glycoside toxicity.

Risk in older adults

Older patients often require smaller doses because kidney function and drug clearance may decline with age. They are also more likely to have medical conditions that increase susceptibility to toxicity.

Rate-slowing drug interactions

Concurrent use of beta blockers or calcium channel blockers can enhance bradycardia and atrioventricular conduction delay.

Drugs that increase glycoside concentrations

Medications such as quinidine, quinine, verapamil, diltiazem, amiodarone, erythromycin, and tetracycline may increase circulating digitalis concentrations.

Reduced renal clearance

Nifedipine, spironolactone, triamterene, and amiloride may reduce renal clearance of digoxin and therefore increase the potential for accumulation.

Additional medication interaction

Warfarin has historically been reported as a possible contributor to increased digoxin concentrations.

Kidney impairment

Renal failure reduces elimination of digoxin and significantly increases the risk of accumulation and toxicity.

Liver impairment

Digitoxin depends more heavily on hepatic metabolism than digoxin. Reduced liver function can therefore impair digitoxin elimination.

Electrolyte risk factors

Low potassium, elevated calcium, and low magnesium can increase myocardial sensitivity to cardiac glycosides and make dysrhythmias more likely.

Other physiologic risk factors

Increased sympathetic nervous system activity and hypothyroidism may also worsen the clinical effects of digitalis toxicity.

Pregnancy considerations

The historical source classified digoxin as FDA Pregnancy Category C under the former pregnancy classification system. This category indicated possible fetal risk based on animal data or insufficient controlled human studies.

Breast-feeding

Digoxin has not generally been considered an absolute contraindication during breast-feeding.

Diagnosis

Differential diagnosis

Other conditions can resemble cardiac glycoside poisoning, particularly when nausea, hypotension, or bradycardia is present.

Toxic causes with similar features

Possible toxicologic alternatives include poisoning from cardiotoxic plants, beta blockers, calcium channel blockers, and class I antiarrhythmic medications.

Non-toxic causes with similar features

Medical causes such as gastroenteritis, intestinal obstruction, myocardial ischemia, hyperkalemia, and other electrolyte disturbances should also be considered.

Early manifestations

Initial symptoms are often vague and may include general weakness, malaise, or nausea before more obvious cardiovascular abnormalities appear.

Progressive toxicity

As poisoning becomes more severe, disturbances in cardiac impulse formation and conduction become increasingly important.

Vital sign abnormalities

Patients may develop a slow heart rate, rapid heart rate, or low blood pressure depending on the type and severity of toxicity.

Visual disturbances

Visual symptoms may include blurred vision, reduced visual clarity, or abnormal color perception. Some patients describe colored halos around objects.

Bradycardia

A reduction in heart rate can result from increased vagal activity and slowed atrioventricular conduction.

Atrioventricular block

Different degrees of atrioventricular block may occur as toxicity interferes with conduction through the atrioventricular node.

Atrial tachycardia

Paroxysmal atrial tachycardia accompanied by conduction block is a classic rhythm disturbance associated with digoxin toxicity.

Ventricular conduction abnormalities

Intraventricular conduction delays and ventricular dysrhythmias may develop in more serious poisoning.

Heart failure

Cardiac glycoside toxicity can worsen cardiac function and may contribute to congestive heart failure in susceptible individuals.

Gastrointestinal symptoms

Nausea, vomiting, loss of appetite, and abdominal discomfort are common and may appear before significant cardiac manifestations.

Potassium elevation

Hyperkalemia frequently occurs in acute, severe digoxin overdose and may indicate significant sodium-potassium ATPase inhibition.

Potassium depletion

Low potassium is more commonly associated with chronic toxicity or concurrent diuretic treatment and can make the myocardium more sensitive to digoxin.

Neurologic symptoms

Severe toxicity may cause headache, weakness, drowsiness, hallucinations, or confusion.

Investigations

Serum digoxin concentration

Measurement of serum digoxin concentration is an important part of evaluating suspected toxicity. The historical therapeutic range cited in the source is approximately 0.5–2 ng/mL.

Serum digitoxin concentration

The historical therapeutic range given for digitoxin is approximately 18–22 ng/mL.

Interpretation of drug levels

A concentration within the usual therapeutic range does not completely exclude toxicity. Electrolyte abnormalities, especially hypokalemia, can increase sensitivity to cardiac glycosides.

Electrocardiogram

An electrocardiogram is essential because nearly every type of cardiac rhythm abnormality has been reported during cardiac glycoside poisoning.

Common ECG changes

Frequently described findings include prolongation of the PR interval and shortening of the corrected QT interval.

Characteristic rhythm abnormalities

Sinus bradycardia, atrioventricular block, and atrial or junctional tachydysrhythmias are strongly associated with clinically important toxicity.

Highly suggestive rhythms

Bidirectional ventricular tachycardia, paroxysmal atrial tachycardia with 2:1 block, and junctional tachycardia are particularly suggestive of digoxin poisoning.

Electrolyte testing

Serum potassium, calcium, and magnesium should be assessed because abnormalities in these electrolytes can significantly alter the severity of cardiac toxicity.

Kidney function testing

Blood urea nitrogen and creatinine should be measured because impaired kidney function can reduce digoxin clearance.

Significance of hyperkalemia

In acute overdose, significant hyperkalemia indicates severe poisoning and may support the need for digoxin-specific antibody therapy.

Significance of hypokalemia

Low potassium increases myocardial sensitivity to digoxin and can promote dangerous rhythm disturbances even when the serum drug concentration is not markedly elevated.

Calcium and magnesium abnormalities

High calcium and low magnesium may further predispose the patient to cardiac dysrhythmias.

Liver function testing

Liver function tests may be useful when digitoxin exposure is suspected because impaired hepatic function can slow its metabolism and increase serum concentrations.

Screening for coingestants

In intentional overdose, acetaminophen and salicylate levels may be measured to identify additional substances that were not initially reported.

Effect of digoxin immune Fab on testing

After digoxin immune Fab is administered, measured serum digoxin concentrations may appear markedly elevated because many laboratory assays detect both antibody-bound and free digoxin.

Digoxin-like immunoreactive substances

Naturally occurring digoxin-like substances can occasionally interfere with laboratory testing and produce an apparent digoxin concentration even without therapeutic digoxin exposure.

Situations associated with assay interference

These substances have been described particularly in newborns and, less commonly, in pregnancy or in patients with significant kidney or liver disease.

Treatment

General approach

Management focuses on stabilizing the patient, identifying dangerous cardiac abnormalities, correcting relevant electrolyte disturbances, and administering digoxin immune Fab when indicated.

Exposure assessment

The amount ingested, timing of exposure, product involved, and presence of any additional substances should be determined whenever possible.

Poison control consultation

Specialist toxicology advice should be obtained when dangerous cardiac dysrhythmias, altered mental status, or other serious manifestations are present.

Atypical clinical findings

Poison-control consultation is also appropriate when the patient’s symptoms do not match the expected pattern of cardiac glycoside poisoning or when another illness, medication interaction, or coingestant complicates management.

Referral for medical assessment

Evaluation in a health-care facility is appropriate when ingestion of more than approximately 2–3 mg of digoxin is suspected, when intentional poisoning is possible, or when clinical toxicity develops.

Reliability concerns

Medical evaluation is also warranted when the patient or caregiver cannot reliably provide observation or an accurate history.

Admission considerations

Patients with symptoms or newly developed ECG abnormalities generally require inpatient treatment, often with intensive cardiac monitoring.

Historical out-of-hospital decontamination

The historical source described induced vomiting with ipecac within 1 hour of an acute ingestion in selected alert patients when medical evaluation would be delayed.

Historical in-hospital decontamination

The source also described gastric emptying procedures for selected patients presenting soon after a large ingestion or with serious manifestations.

Activated charcoal

A single dose of activated charcoal was described following substantial recent ingestion when clinically appropriate and when airway protection could be ensured.

Antidote treatment

Digoxin immune Fab

Digoxin immune Fab consists of antibody fragments that bind circulating digoxin and related cardiac glycosides, reducing the amount of active drug available to interact with cardiac tissue.

Cardiovascular instability

Use of digoxin immune Fab is indicated when poisoning causes serious cardiovascular instability, including clinically significant hypotension, symptomatic bradycardia, or potentially unstable dysrhythmias.

Rapidly worsening toxicity

Antibody treatment should also be considered when gastrointestinal or cardiovascular manifestations are progressing rapidly.

Severe hyperkalemia

A serum potassium concentration greater than approximately 5.5 mEq/L in acute digoxin poisoning is a major indicator of severe toxicity and has historically been considered an indication for digoxin immune Fab.

Cardiac arrest

Digoxin immune Fab may still provide benefit during cardiac arrest caused by cardiac glycoside poisoning when treatment can be administered promptly.

Empirical dosing

The historical source describes empirical administration of multiple vials in critically ill patients with strongly suspected digoxin poisoning when a serum concentration is not yet available.

Dose calculation

The precise dose of digoxin immune Fab depends on factors such as the estimated amount ingested, measured serum digoxin concentration, body weight, and severity of clinical toxicity.

Adjunctive treatment

Potassium replacement

Low potassium should be corrected cautiously because hypokalemia increases the myocardium’s sensitivity to cardiac glycosides.

Treatment of dysrhythmias

Digoxin immune Fab is the preferred treatment when dangerous rhythm disturbances are directly related to cardiac glycoside poisoning.

Ventricular dysrhythmias

Lidocaine and phenytoin have historically been used to manage ventricular rhythm disturbances associated with digitalis toxicity.

Supraventricular dysrhythmias

Magnesium or phenytoin may be considered for selected supraventricular tachydysrhythmias when clinically appropriate.

Bradycardia management

Atropine may be used for clinically significant bradycardia while definitive treatment is being arranged.

Circulatory support

Vasopressors may be necessary during initial stabilization of patients with severe hypotension or shock, particularly before digoxin immune Fab becomes available or takes effect.

Therapies to avoid

The historical source cautions that procainamide, quinidine, disopyramide, and propranolol may aggravate atrioventricular conduction block in digitalis poisoning.

Historical calcium warning

The original source advises against calcium administration in severe digoxin toxicity because of concern for worsening cardiac excitability. Management of calcium abnormalities in suspected digoxin poisoning should follow current toxicology guidance.

Follow-up

Cardiac monitoring

Symptomatic patients should undergo continuous cardiac rhythm monitoring because potentially serious dysrhythmias may appear or change rapidly.

Hemodynamic monitoring

Blood pressure and overall circulatory status should be followed closely, particularly in patients with significant bradycardia, tachydysrhythmia, or shock.

Potassium monitoring

Serum potassium should be checked repeatedly during significant poisoning because potassium abnormalities can change as treatment progresses.

Expected recovery

Complete recovery is common when toxicity is recognized and treated promptly, although the patient’s underlying cardiac or systemic disease can complicate the clinical course.

Complications of severe poisoning

Prolonged hypotension or inadequate oxygen delivery may result in secondary organ injury even after the direct effects of digoxin have been reversed.

Response to digoxin immune Fab

Clinical improvement can occur relatively rapidly after appropriate digoxin immune Fab treatment, particularly when severe shock, hypoxia, or another toxic exposure has not already produced complications.

Emergency department discharge

Patients who remain asymptomatic, have a non-toxic digoxin concentration, normal electrolytes, and a normal ECG may be considered for discharge after an appropriate observation period and any necessary decontamination.

Observation period

The historical source describes approximately 6 hours of observation before discharge in otherwise stable patients following acute exposure.

Hospital discharge

Hospitalized patients may be discharged after cardiac abnormalities and other toxic manifestations have resolved or stabilized sufficiently for safe outpatient care.

Psychiatric assessment

Mental health evaluation should be considered when the exposure was deliberate or when self-harm is suspected.

Clinical pitfalls

Nonspecific presentation

Digitalis toxicity may initially resemble many other illnesses because early manifestations such as nausea, weakness, or confusion are nonspecific.

Therapeutic levels do not exclude toxicity

Patients can experience clinically significant digitalis toxicity despite serum digoxin concentrations that fall within the usual therapeutic range, particularly when electrolyte abnormalities or interacting medications are present.

Delayed treatment

Significant cardiac glycoside poisoning can deteriorate rapidly, making prompt recognition and treatment important.

Availability of antidote

Facilities treating severe digoxin poisoning need timely access to adequate quantities of digoxin immune Fab because insufficient availability may delay definitive therapy.

Recurrent toxicity

Clinical toxicity may recur after digoxin immune Fab treatment, particularly in patients with impaired kidney function or when the administered antibody dose is insufficient.

Classification

ICD-9-CM 972 refers to poisoning by substances that primarily affect the cardiovascular system.

Toxicology

Diethyltoluamide (DEET)

General overview

Diethyltoluamide, commonly known as DEET, is a widely used insect-repellent ingredient. Products intended for application to the skin are available without prescription and may contain concentrations ranging from approximately 5% to 100%.

Available preparations

DEET is present in many commercial insect repellents and may be supplied as aerosols, pump sprays, lotions, liquids, creams, sticks, or treated wipes. The concentration varies considerably between products, with some preparations containing only a small percentage of DEET and others approaching 100%.

Main use

The primary purpose of DEET is to repel mosquitoes, ticks, and other biting insects when applied to exposed skin or used according to the manufacturer’s instructions.

Toxic dose

Serious toxicity may occur after ingestion of approximately 25–50 mL of a highly concentrated preparation. Repeated excessive application to the skin can also result in significant poisoning.

Normal skin exposure

When DEET is used on the skin at recommended doses, adverse effects are uncommon. Toxicity becomes more likely when large amounts are repeatedly applied over several days.

Mechanism of toxicity

The precise mechanism responsible for DEET poisoning has not been fully established. Its major toxic effects primarily involve the central nervous system.

Absorption through the skin

A substantial proportion of DEET applied to the skin can enter the body. Approximately half of a topical dose may be absorbed within about 6 hours, with peak blood concentrations occurring around 1 hour after application.

Tissue accumulation

DEET and its metabolic products may remain in the skin and fatty tissues for prolonged periods. Persistence for several weeks after application suggests that repeated exposure may allow accumulation within the body.

Frequency of serious poisoning

Although DEET is one of the most commonly used insect repellents, severe poisoning is uncommon when products are used correctly.

Circumstances of severe toxicity

Serious illness and death have been reported mainly after intentional or accidental ingestion of concentrated preparations or repeated application of excessive quantities to the skin.

Common causes of exposure

Most cases of toxicity result from inappropriate or excessive product use rather than normal application.

Exposure in young children

Repeated application of large amounts of DEET-containing repellent to young children has historically been an important cause of significant toxicity because children can absorb proportionally larger amounts through the skin.

Intentional exposure

In very young infants, inappropriate exposure may raise concern for neglect or improper administration. In older children and adolescents, deliberate ingestion or self-harm should be considered when supported by the circumstances.

Damaged skin

Broken, irritated, or unusually permeable skin may increase absorption of DEET and therefore increase the risk of systemic toxicity.

Increased absorption in children

Young children have relatively permeable skin and may absorb clinically important amounts of DEET following frequent or excessive application.

Seizure-related interactions

Medications or substances that reduce the seizure threshold may increase the likelihood of convulsions in a patient experiencing significant DEET toxicity.

Drug metabolism interactions

DEET may influence hepatic cytochrome P450 enzyme activity. This could potentially alter the effects of medications metabolized through these pathways, including some anticonvulsants and other drugs.

Pregnancy considerations

Animal studies have suggested that DEET can be absorbed through the skin during pregnancy. Historical experimental findings raised concern regarding possible fetal effects at sufficient exposure levels.

Exposure reduction during pregnancy

When appropriate, physical methods of insect protection such as mosquito nets, protective clothing, and environmental controls can reduce the amount of repellent required on the skin.

Diagnosis

Differential diagnosis

A number of toxic and medical conditions may produce seizures resembling those associated with severe DEET poisoning.

Toxic causes of seizures

Possible toxicologic causes include central nervous system stimulants, certain antiarrhythmic drugs, isoniazid, tricyclic antidepressants, monoamine oxidase inhibitors, antipsychotic medications, antihistamines, and numerous other substances.

Non-toxic causes of seizures

Medical explanations such as low blood glucose, abnormal sodium concentration, oxygen deprivation, hypothermia, hypothyroidism, intracranial bleeding, central nervous system infection, or an underlying seizure disorder should also be considered.

Main clinical pattern

The characteristic acute pattern of serious DEET poisoning involves central nervous system depression followed by seizures. Convulsions may occur repeatedly in severe cases.

Vital sign abnormalities

Marked overdose may produce a rapid heart rate, low blood pressure, and suppression of normal respiratory activity.

Eye exposure

Direct contact between DEET and the eyes can irritate the cornea and surrounding mucous membranes.

Skin effects

Superficial dermatitis is among the most frequently reported adverse reactions following topical DEET use.

Cardiovascular effects

Sinus tachycardia may occur during significant poisoning. Severe hypotension and cardiovascular collapse have also been reported, although these complications are uncommon.

Respiratory effects

Profound central nervous system depression can interfere with normal breathing and may eventually cause respiratory failure.

Gastrointestinal effects

Nausea and vomiting may follow ingestion of DEET or substantial absorption after heavy skin exposure.

Liver effects

Severe poisoning may occasionally produce acute chemical hepatitis.

Liver injury after repeated use

Rare cases of idiosyncratic toxic hepatitis have also been reported following repeated exposure.

Early neurologic effects

Initial neurologic findings may include poor coordination, irritability, confusion, and disorientation.

Progressive neurologic depression

As toxicity becomes more severe, patients may become increasingly drowsy and less responsive as central nervous system activity is suppressed.

Severe neurologic toxicity

Major poisoning may progress to unresponsiveness, coma, flaccid paralysis, loss of corneal reflexes, reduced deep-tendon reflexes, and recurrent seizures.

Life-threatening complications

Death in severe poisoning may result from respiratory failure associated with profound central nervous system depression.

Investigations

Testing in asymptomatic patients

Patients who remain completely asymptomatic may not require routine laboratory investigations.

Basic metabolic testing

Serum electrolytes, blood urea nitrogen, creatinine, and glucose may be measured in symptomatic patients to identify metabolic abnormalities contributing to central nervous system manifestations.

Oxygenation assessment

Pulse oximetry should be used to assess oxygenation in symptomatic patients. Arterial blood gas analysis may be considered when significant respiratory compromise is present.

Liver assessment

Serum liver enzyme measurements may be useful when chemical hepatitis is suspected.

Screening in overdose

An electrocardiogram and serum acetaminophen and salicylate concentrations may be considered in overdose cases to identify possible hidden coingestants.

Evaluation of altered mental status

When the diagnosis remains uncertain, additional investigations such as brain imaging, lumbar puncture, bacterial cultures, or other appropriate studies may be required to exclude neurologic or infectious causes.

DEET concentration testing

Blood DEET concentrations can be measured by some specialized laboratories, but the clinical value of these levels for guiding treatment is uncertain.

Treatment

Initial management

Early treatment should focus on removing further exposure, protecting the airway, maintaining adequate breathing and circulation, and rapidly controlling seizures when present.

Exposure history

The amount of DEET involved, concentration of the product, route of exposure, and time since exposure should be established whenever possible. Any additional substances involved should also be identified.

Poison control consultation

Specialist poison-control or toxicology advice should be considered when the clinical presentation does not fit typical DEET toxicity or when coingestion, drug interactions, or underlying illness complicate the case.

Referral for medical assessment

Evaluation in a health-care facility is appropriate when intentional poisoning is suspected, the patient or caregiver cannot provide reliable observation, signs of toxicity develop, or another exposure or illness increases risk.

Admission considerations

Hospital admission is generally appropriate for patients who develop altered mental status, respiratory depression, coma, or seizures.

Out-of-hospital gastrointestinal management

The historical source advises against inducing vomiting because seizures can begin suddenly after significant DEET ingestion and may create an aspiration risk.

Skin decontamination

Following substantial dermal exposure, contaminated skin should be thoroughly washed with soap and water to remove remaining product and limit further absorption.

Hospital skin decontamination

Patients presenting to hospital after significant skin exposure should also have affected areas cleaned thoroughly with soap and water.

Gastric aspiration

The historical source describes nasogastric aspiration as a possible consideration in selected patients who present within approximately 1 hour of a major ingestion or who already show serious toxicity.

Activated charcoal

A single dose of activated charcoal was historically recommended after a substantial recent ingestion when clinically appropriate and when the patient’s airway could be safely protected.

Specific antidote

There is no specific antidote capable of directly reversing DEET poisoning.

Seizure management

Patients who develop seizures require immediate attention to airway protection and oxygenation.

Initial anticonvulsant therapy

A benzodiazepine is generally used as first-line medication for acute seizure control.

Persistent seizures

If convulsions continue or recur despite initial treatment, additional anticonvulsant therapy such as phenobarbital may be considered according to clinical circumstances.

Follow-up

Cardiac monitoring

Symptomatic patients should have their heart rate, rhythm, and cardiovascular status monitored because significant poisoning can produce tachycardia, hypotension, or circulatory instability.

Respiratory monitoring

Continuous observation of respiratory function is important in symptomatic patients because central nervous system depression may progress to respiratory failure.

Expected recovery

Most cases of DEET toxicity improve within approximately 24 hours once exposure has stopped and appropriate supportive treatment has been provided.

Severe poisoning

Patients with major neurologic or respiratory toxicity may require hospitalization beyond 24 hours, depending on the persistence of symptoms and complications.

Neurologic complications

Long-term consequences from repeated seizures or oxygen deprivation are uncommon but may occur following particularly severe poisoning.

Persistent neuropsychiatric effects

Some severely affected individuals may experience subtle cognitive, behavioral, or neuropsychiatric abnormalities lasting for several weeks or months after the acute episode.

Emergency department discharge

Patients may be considered for discharge after appropriate decontamination and an observation period of approximately 4–6 hours when they remain asymptomatic and no additional medical concerns are present.

Hospital discharge

Patients admitted to hospital may be discharged when toxic manifestations have resolved or become clinically stable and further inpatient treatment is no longer required.

Psychiatric assessment

A mental health evaluation should be considered when exposure was deliberate or when attempted self-harm is suspected.

Patient education

Use in young children

Highly concentrated DEET preparations should be used cautiously in small children. Products should be selected and applied according to current manufacturer and public-health recommendations.

Avoiding excessive application

Repeated application more frequently than recommended should be avoided because unnecessary accumulation on the skin can increase systemic absorption.

Following product instructions

Parents and caregivers should follow the application frequency, age restrictions, concentration guidance, and other safety instructions supplied with the specific insect-repellent product.

Washing after exposure

When continued protection is no longer required, treated skin can be washed with soap and water to remove residual repellent, particularly in children.

Clinical pitfalls

Alternative diagnoses

Altered mental status, seizures, or coma should not automatically be attributed to DEET exposure. Other toxicologic, neurologic, infectious, and metabolic causes should remain under consideration.

Failure to decontaminate

Clinicians should not overlook skin decontamination after significant dermal exposure because residual DEET on the skin may continue to be absorbed.

Classification

ICD-9-CM 989.4 refers to toxic effects from certain nonmedicinal substances, including pesticides not otherwise classified.

Toxicology

Diethylstilbestrol (DES)

General overview

Diethylstilbestrol, commonly known as DES, is a synthetic nonsteroidal compound belonging to the stilbene group. Its biological activity resembles that of naturally occurring estrogen.

Available forms

DES has been produced in several formulations, including oral tablets in strengths ranging from 0.1 mg to 5 mg, rectal suppositories, and an intravenous preparation containing 250 mg in 5 mL.

Therapeutic uses

Historically, DES was used as palliative treatment for advanced, inoperable prostate cancer and for certain breast cancers affecting men and postmenopausal women.

Reproductive and hormonal uses

Other past uses included postcoital contraception within 72 hours of intercourse, management of menopausal vasomotor symptoms, relief of postpartum breast engorgement, suppression of lactation after childbirth, and hormonal feminization.

Toxic dose

A large single overdose usually produces gastrointestinal symptoms such as nausea, vomiting, and diarrhea rather than severe systemic poisoning.

Effects of chronic exposure

Long-term ingestion at therapeutic doses is more likely to cause significant adverse effects. Exposure during pregnancy may also result in harmful effects on the developing fetus.

Mechanism of toxicity

During prolonged treatment, DES behaves similarly to endogenous estrogen and can therefore influence estrogen-sensitive tissues and physiological processes.

Prenatal exposure in females

Females exposed to DES before approximately the 18th week of fetal development have been reported to experience higher rates of irregular or infrequent menstruation, infertility, spontaneous abortion, and premature delivery later in life.

Prenatal exposure in males

Males exposed to DES during early fetal development may have an increased risk of epididymal cysts, undescended testes, reduced gonadal function, and decreased sperm production.

Cancer association

Females exposed to DES before birth and women who received DES therapeutically have demonstrated an increased incidence of vaginal clear-cell adenocarcinoma and cervical abnormalities, including adenocarcinoma.

Other malignancies

Although several additional cancers have been investigated in relation to DES exposure, definite causal relationships have not been established for all of them.

Major risk factor

Use of DES during pregnancy represents an important risk because the developing fetus may be exposed to its estrogenic effects.

Drug and disease interaction

DES may stimulate or accelerate the growth of certain hormone-responsive cancers, particularly in premenopausal women.

Pregnancy considerations

DES was formerly classified as FDA Pregnancy Category X because evidence demonstrated fetal abnormalities or significant fetal risk, and the potential harm during pregnancy was considered greater than any expected therapeutic benefit.

Diagnosis

Skin manifestations

Skin reactions, including rashes, may develop in individuals exposed to DES.

Cardiac effects

Prolonged DES use has been associated with an increased occurrence of myocardial ischemia.

Thrombotic effects

Chronic treatment may increase the risk of blood clot formation. Reported complications include cerebrovascular events, deep-vein thrombosis, pulmonary embolism, mesenteric thrombosis, and retinal vascular thrombosis.

Gastrointestinal effects

Acute overdose commonly produces nausea, vomiting, abdominal discomfort, and abdominal distension.

Liver effects

Long-term DES exposure may occasionally lead to hepatitis accompanied by cholestatic jaundice.

Renal and metabolic effects

Urethral strictures and porphyria have been reported during prolonged therapy.

Fluid retention

Chronic treatment may contribute to retention of body fluid and the development of edema.

Reproductive effects

Women receiving DES over an extended period may experience vaginal bleeding, painful menstruation, or absence of menstrual periods.

Calcium abnormalities

Elevated serum calcium may occur, especially in immobilized patients or in individuals with osteoporosis, kidney impairment, or metastatic cancer involving bone.

Hormonal effects in males

Long-term DES exposure in males may cause breast enlargement, breast tenderness, excessive hair growth, hair loss, or other changes related to altered hormonal activity.

Investigations

Testing after isolated ingestion

Extensive laboratory testing may not be necessary for an asymptomatic patient following a single acute ingestion.

Blood count

For individuals receiving chronic therapy, a complete blood count may be performed to identify possible abnormalities involving bone marrow function.

Calcium assessment

Serum calcium should be considered when there is concern for abnormal calcium concentrations, including either reduced or elevated levels.

Cardiovascular investigations

An electrocardiogram, chest radiograph, and other appropriate investigations may be required when myocardial ischemia or thromboembolic disease is suspected.

Liver assessment

Measurement of liver enzymes can assist in identifying possible chemically induced hepatitis associated with chronic exposure.

Screening for additional substances

In an overdose setting, serum acetaminophen and salicylate concentrations may be measured when there is a possibility of an unrecognized coingestion.

Treatment

General approach

Management is primarily directed toward the patient’s clinical condition and any complications that develop, as a single DES ingestion generally has relatively low acute toxicity.

Poison control consultation

Specialist toxicology or poison-control advice should be considered when severe or persistent symptoms develop or when a coingestant, drug interaction, or underlying illness makes the case more complicated.

Referral for medical assessment

Evaluation in a health-care facility is appropriate when toxic effects appear or when another substance, medication interaction, or pre-existing disease may increase clinical risk.

Admission considerations

Hospital admission may be required when intentional self-harm is suspected or when significant hematologic or cardiovascular complications develop.

Accidental ingestion

Children and adults who remain well following an isolated accidental ingestion may often be managed with observation outside the hospital when appropriate medical guidance and reliable supervision are available.

Out-of-hospital decontamination

The historical source advises against the use of ipecac following an isolated DES ingestion because a single exposure generally produces limited acute toxicity.

In-hospital decontamination

The historical source also describes gastric lavage as rarely necessary because severe acute toxicity is uncommon. It was mainly considered when a dangerous coingestant was present or when other serious clinical circumstances justified gastric emptying.

Activated charcoal

A single dose of activated charcoal was historically described for a substantial recent ingestion when clinically appropriate and when the airway could be adequately protected.

Specific antidote

No specific antidote is available for DES poisoning. Treatment therefore focuses on supportive care and management of individual complications.

Follow-up

Long-term monitoring

Women who previously received DES and females who were exposed to DES before birth require appropriate long-term medical surveillance because some complications may appear years after the original exposure.

Gynecologic surveillance

Regular pelvic examinations and appropriate cytologic screening have historically been recommended for women at increased risk because of prenatal or therapeutic DES exposure.

Monitoring for complications

Additional investigations should be based on the complications being considered. For example, symptoms suggesting pulmonary embolism require appropriate cardiovascular and respiratory evaluation.

Expected course after acute overdose

An acute overdose most commonly produces gastrointestinal symptoms that persist for several hours and then gradually resolve.

Prognosis after chronic exposure

For individuals exposed to DES over a prolonged period, the eventual outcome depends largely on whether significant complications such as thromboembolic disease, cardiac ischemia, reproductive abnormalities, or malignancy develop.

Discharge criteria

Patients may be discharged from the emergency department or hospital once toxic effects have resolved or become clinically stable and no further acute medical intervention is required.

Psychiatric evaluation

Mental health assessment may be appropriate when ingestion was intentional or when self-harm is suspected.

Clinical pitfalls

Inadequate long-term surveillance

Failure to monitor individuals with prolonged DES exposure may allow hematologic, reproductive, gynecologic, or cardiovascular complications to develop without early recognition.

Diagnostic awareness

Clinical findings should not automatically be attributed to DES exposure. Other medical conditions, medications, and toxic substances should also be considered when the patient’s presentation is unusual.

Classification

ICD-9-CM 962 refers to poisoning caused by hormones and synthetic hormonal substitutes.

TOXICOLOGY

DEXTROMETHORPHAN

General Overview

Dextromethorphan is a synthetic compound related structurally to codeine. Although it has some opioid-like characteristics at excessive doses, its main clinical purpose is suppression of coughing rather than pain relief.

Common Preparations and Uses

Dextromethorphan is widely found in nonprescription cough and cold remedies. When taken within the recommended dosage range, it generally does not produce clinically important analgesia, sedation, or suppression of breathing.

Toxicity Threshold

Toxic effects are more likely when a person consumes an amount exceeding approximately ten times the usual therapeutic dose.

Mechanism of Toxicity

When taken in excessive amounts, dextromethorphan may produce mild opioid-like effects on the central nervous system. It also affects serotonin activity by reducing serotonin reuptake, which can contribute to serotonin toxicity under certain circumstances.

Frequency of Poisoning

Clinically significant poisoning from dextromethorphan is relatively uncommon. Severe toxicity occurs less frequently than mild or moderate intoxication.

Circumstances of Exposure

Many clinically important overdoses are intentional. In very young children, particularly those younger than 1 year, inappropriate administration, neglect, or abuse should be considered. In older children and adolescents, deliberate ingestion or self-harm may need to be evaluated.

Important Drug Interactions

Dextromethorphan may interact with medications that increase serotonin activity. Use with monoamine oxidase inhibitors or selective serotonin reuptake inhibitors can, although rarely, contribute to serotonin syndrome.

Pregnancy Considerations

Available reports have not clearly linked dextromethorphan exposure with congenital malformations when used during pregnancy.

DIAGNOSIS

Conditions That May Resemble Toxicity

Respiratory slowing and central nervous system depression can result from many other substances. Possible alternatives include sedative medications, opioids, alcohol, antidepressants, and other toxic agents.

Eye and Head Findings

Visual disturbance may occur during intoxication. The pupils may become either enlarged or constricted, and involuntary rhythmic eye movements may also be present.

Cardiovascular Findings

An overdose may cause an increased heart rate and elevated blood pressure.

Gastrointestinal Findings

Digestive symptoms may include nausea, vomiting, diarrhea, or constipation.

Respiratory Findings

A very large ingestion can interfere with normal breathing and may lead to respiratory depression.

Neurologic and Behavioral Findings

Neurologic toxicity may present with unusual behavior, agitation, excessive activity, exaggerated reflexes, increased muscle tone, hallucinations, psychotic behavior, drowsiness, poor coordination, slurred speech, or seizures.

Features of Severe Poisoning

Marked intoxication may progress from profound drowsiness to stupor or coma.

INVESTIGATIONS

Testing in Asymptomatic Patients

Routine laboratory testing is often unnecessary when the patient has no symptoms and there is no concern for another substance or medical condition.

Basic Laboratory Assessment

Electrolytes, blood urea nitrogen, and creatinine may be measured when altered mental status is present or another medical explanation needs to be excluded.

Evaluation for Combination Products

Because dextromethorphan is often included in products containing other medications, ethanol and acetaminophen levels may be useful when a mixed preparation is suspected.

Assessment of Breathing

Patients with reduced respiratory function should have oxygen saturation monitored. Arterial blood gas testing may be considered when clinically indicated.

Evaluation of Altered Mental Status

Additional investigations should be selected according to the patient’s clinical condition and other possible causes of altered consciousness.

Intentional Ingestion

When an overdose is deliberate, assessment may include an electrocardiogram together with serum acetaminophen and salicylate measurements to identify potentially hidden coingestants.

TREATMENT

Main Treatment Approach

Management is mainly supportive. Airway, breathing, and circulation should be stabilized, and advanced resuscitative measures should be provided when required.

When Poison-Control Advice Is Appropriate

Specialist toxicology or poison-control advice is appropriate when hallucinations, abnormal mental status, serious symptoms, unexpected clinical findings, medication interactions, coingestants, or significant underlying disease complicate the case.

When Medical Evaluation Is Needed

Assessment at a health-care facility is appropriate when intentional self-harm or harm by another person is suspected, symptoms of toxicity are present, supervision at home is unreliable, or another drug or illness creates additional risk.

Admission Considerations

Patients whose symptoms persist should remain under medical evaluation until the abnormalities improve and serious complications have been excluded.

Gastrointestinal Decontamination Outside Hospital

The historical source describes the use of ipecac within 1 hour of ingestion in selected alert patients when medical evaluation would be delayed.

Gastrointestinal Decontamination in Hospital

The historical source also describes gastric emptying measures in selected patients presenting soon after a large ingestion or when major toxicity is present.

Activated Charcoal

A single dose of activated charcoal was described for substantial recent ingestion when airway protection and other clinical circumstances permit its use.

Naloxone

Naloxone has occasionally improved respiratory or central nervous system depression following dextromethorphan poisoning. Its response, however, is unpredictable and it may not produce improvement in every patient.

FOLLOW-UP

Airway Observation

Patients with severe intoxication require careful respiratory monitoring because deterioration in airway protection or breathing may occur.

Monitoring for Serotonin Toxicity

Extra observation is required when dextromethorphan has been taken together with serotonergic drugs such as an MAO inhibitor or SSRI.

Temperature Monitoring

Body temperature should be followed in patients with significant intoxication because serotonin-related toxicity may cause abnormal temperature elevation.

Expected Recovery

Most patients experience relatively mild effects and recover without major complications. Symptoms commonly improve within approximately 24 hours.

Discharge Considerations

Patients who remain free of symptoms may be considered for discharge following an appropriate observation period, commonly around 4 to 6 hours, provided no other medical or toxicologic concerns are identified.

Mental Health Assessment

Psychiatric assessment may be required when the ingestion was deliberate or when self-harm is suspected.

CLINICAL PITFALLS

Avoiding Diagnostic Anchoring

Altered consciousness should not automatically be attributed to dextromethorphan. Other toxic, metabolic, neurologic, and medical causes should remain part of the assessment.

Classification

ICD-9-CM 965.09 refers to poisoning involving expectorants and cough preparations containing codeine-related compounds.

DIETHYLSTILBESTROL (DES)

General Overview

Diethylstilbestrol, commonly abbreviated as DES, is a synthetic nonsteroidal compound that produces effects similar to naturally occurring estrogen.

Available Preparations

DES has historically been supplied as oral tablets in several strengths, as well as in rectal and intravenous preparations.

Historical Therapeutic Uses

Previous clinical applications included palliative treatment of advanced prostate cancer and certain breast cancers. DES was also used for emergency postcoital contraception, menopausal symptoms, postpartum breast discomfort, suppression of lactation, and hormonal feminization.

Acute Toxicity

A single large ingestion usually causes gastrointestinal symptoms rather than severe systemic poisoning. Nausea, vomiting, and diarrhea are among the more typical acute effects.

Effects of Long-Term Exposure

Repeated therapeutic exposure is more concerning than a single overdose because prolonged estrogenic effects may result in significant adverse events.

Fetal Risk

Exposure during pregnancy can affect fetal development and has historically been associated with abnormalities in individuals exposed before birth.

Mechanism of Action

During chronic administration, DES behaves similarly to endogenous estrogen and can affect multiple estrogen-sensitive tissues and organ systems.

Effects in Females Exposed Before Birth

Females exposed to DES during early fetal development have been reported to experience increased rates of menstrual abnormalities, infertility, miscarriage, and premature delivery.

Effects in Males Exposed Before Birth

Male fetal exposure has been associated with epididymal cysts, undescended testes, reduced gonadal function, and impaired sperm production.

Cancer Association

Prenatal DES exposure in females has been associated with an increased occurrence of vaginal clear-cell adenocarcinoma. Cervical abnormalities and other reproductive tract complications have also been described.

Major Risk Factor

Administration of DES during pregnancy represents the most important historical risk factor for fetal exposure.

Cancer-Related Interaction

Because DES has estrogen-like activity, it may stimulate the growth of certain hormone-sensitive malignancies, particularly in susceptible patients.

Pregnancy Classification

DES was formerly classified as FDA Pregnancy Category X because fetal harm had been demonstrated and the risks of use during pregnancy outweighed any potential therapeutic benefit.

DIAGNOSIS

Skin Manifestations

Some patients receiving DES have developed skin eruptions or rashes.

Cardiac Effects

Long-term exposure has been associated with an increased risk of myocardial ischemia.

Thrombotic Complications

Chronic DES use has also been linked with blood clot formation, including stroke, deep-vein thrombosis, pulmonary embolism, mesenteric thrombosis, and retinal vascular thrombosis.

Gastrointestinal Effects

Following an acute overdose, patients may experience nausea, vomiting, abdominal discomfort, or abdominal distension.

Liver Effects

Prolonged DES therapy may occasionally cause liver injury, including hepatitis accompanied by cholestatic jaundice.

Renal and Metabolic Effects

Urethral narrowing and porphyria have been reported during long-term exposure.

Fluid Balance

Chronic estrogenic activity may promote fluid retention and peripheral edema.

Reproductive Effects

Women receiving DES may develop abnormal vaginal bleeding, painful menstruation, or absence of menstrual periods.

Calcium Disturbance

Hypercalcemia may occur, particularly in immobilized patients or those with osteoporosis, impaired kidney function, or metastatic disease involving bone.

Hormonal Effects in Males

Long-term exposure in males may lead to breast enlargement, breast tenderness, changes in body hair, excessive hair growth in certain areas, or hair loss.

INVESTIGATIONS

Acute Asymptomatic Exposure

Patients who remain well after an isolated acute ingestion may not require extensive laboratory testing.

Blood Count

For patients undergoing chronic treatment, a complete blood count may be useful to identify possible bone-marrow abnormalities.

Calcium Measurement

Serum calcium can be assessed when there is concern for abnormal calcium regulation, including hypercalcemia.

Cardiovascular Investigation

An electrocardiogram, chest imaging, and additional cardiovascular tests may be required when cardiac ischemia or thromboembolic disease is suspected.

Liver Assessment

Liver enzymes may be measured to evaluate possible drug-related hepatic injury.

Screening for Other Ingestions

In an overdose situation, acetaminophen and salicylate levels may be obtained when an unrecognized coingestion is possible.

TREATMENT

General Management

Treatment depends mainly on the patient’s symptoms and any complications that develop, as isolated acute DES poisoning is usually associated with relatively low immediate toxicity.

Poison-Control Consultation

Specialist toxicology advice should be considered when symptoms are severe, prolonged, unusual, or complicated by another medication, coingestant, or underlying illness.

Referral for Medical Assessment

Patients who develop clinically significant symptoms should be evaluated in a health-care facility, particularly when another substance or medical condition could increase risk.

Hospital Admission

Inpatient management may be required when intentional self-harm is involved or when major cardiovascular or hematologic complications develop.

Accidental Single Exposure

An otherwise well child or adult with an isolated accidental ingestion may often be observed without hospital admission when appropriate medical advice and supervision are available.

Out-of-Hospital Decontamination

The historical source advises against using ipecac after an isolated DES ingestion because acute toxicity is generally low.

Hospital Decontamination

Gastric lavage is rarely necessary following DES ingestion because major acute toxicity is uncommon. It was historically considered mainly when a dangerous coingestant was involved or another strong indication existed.

Activated Charcoal

The source describes a single dose of activated charcoal for substantial recent ingestion when clinically appropriate.

Specific Antidote

There is no specific antidote available for DES poisoning.

FOLLOW-UP

Long-Term Gynecologic Surveillance

Women who received DES and women exposed to DES before birth require appropriate gynecologic follow-up because of the possibility of delayed reproductive tract complications.

Screening

Periodic pelvic examination and cytologic screening have historically been recommended for individuals at increased risk from DES exposure.

Monitoring for Complications

Follow-up investigations should be guided by the complication being considered. For example, patients with symptoms suggestive of pulmonary embolism require appropriate cardiopulmonary assessment.

Expected Course After Acute Overdose

A single acute overdose usually produces gastrointestinal symptoms lasting several hours before spontaneous improvement occurs.

Long-Term Prognosis

For patients with prolonged exposure, the clinical outcome depends mainly on whether serious complications such as thromboembolic disease, cardiac ischemia, or malignancy develop.

Discharge Criteria

Hospital or emergency department discharge may be considered after acute toxic effects have resolved or become medically stable.

Psychiatric Assessment

Mental health evaluation may be appropriate when ingestion occurred intentionally or self-harm is suspected.

CLINICAL PITFALLS

Importance of Long-Term Monitoring

Failure to recognize and monitor the delayed hematologic, cardiovascular, reproductive, and gynecologic effects associated with chronic DES exposure may allow complications to progress without early detection.

Classification

ICD-9-CM 962 refers to poisoning involving hormones and synthetic hormonal substitutes.

I kept the same core medical information but made the structure and wording substantially more distinct, with a separate heading and invisible spacing for every paragraph.

Toxicology – Cyclosporine

Core Concept

Cyclosporine is a calcineurin-inhibitor immunosuppressant with a narrow therapeutic index and extensive drug-interaction potential. Acute oral overdose is often surprisingly well tolerated, whereas clinically important toxicity more commonly develops from chronic excessive exposure, formulation errors, CYP3A4/P-glycoprotein interactions, renal dysfunction, or accidental intravenous overdose.

The characteristic toxicity pattern is:

Excess cyclosporine exposure → renal vasoconstriction + endothelial/neural toxicity → AKI + hypertension + hyperkalemia/hypomagnesemia + tremor/encephalopathy/PRES ± hepatotoxicity

The most important management principles are:

Stop or reduce cyclosporine, identify the cause of excessive exposure, monitor whole-blood concentrations and renal function, correct electrolyte/BP abnormalities, and provide supportive care.

There is no specific antidote, and cyclosporine is not effectively removed by hemodialysis or charcoal hemoperfusion.

Current Uses

Systemic cyclosporine remains an important immunosuppressant in kidney, liver, and heart transplantation. Modified oral formulations are also FDA-labeled for severe active rheumatoid arthritis inadequately responsive to methotrexate and for severe recalcitrant plaque psoriasis in selected adults.

Cyclosporine is also widely used in specialist practice for other immune-mediated diseases.

Modern ophthalmic cyclosporine preparations—including formulations such as Restasis and Cequa—are used for ocular surface inflammatory disease/dry eye. These topical ophthalmic preparations have very different systemic exposure and should not be confused toxicologically with oral or IV cyclosporine.

The older description of routine rectal or pulmonary-aerosol cyclosporine formulations does not reflect standard current U.S. systemic formulations.

Sandimmune Versus Modified Cyclosporine – Critical Formulation Issue

One of the most important practical safety points is that Sandimmune and modified/microemulsion cyclosporine formulations such as Neoral are not bioequivalent and are not freely interchangeable milligram-for-milligram.

Modified cyclosporine has more predictable and generally greater bioavailability. Switching between formulations without appropriate supervision can lead either to excessive exposure and toxicity or to insufficient immunosuppression and graft rejection. Current Sandimmune labeling specifically warns that conversion between Sandimmune and Neoral requires increased concentration monitoring and possible dosage adjustment.

Therefore:

A formulation substitution can itself be the cause of cyclosporine toxicity.

Medication reconciliation should identify the exact formulation, concentration, dose, timing, and whether a recent product switch occurred.

Mechanism of Immunosuppression

Cyclosporine enters lymphocytes and binds the intracellular immunophilin cyclophilin. The cyclosporine–cyclophilin complex then inhibits calcineurin, preventing dephosphorylation and nuclear translocation of NFAT.

This reduces transcription of interleukin-2 and other T-cell activation genes, thereby suppressing activation and proliferation of T lymphocytes.

A useful sequence is:

Cyclosporine + cyclophilin → calcineurin inhibition → ↓ NFAT activation → ↓ IL-2 → ↓ T-cell activation

This is why cyclosporine is classified as a calcineurin inhibitor, along with tacrolimus.

Mechanisms of Toxicity

Cyclosporine toxicity is not simply “too much immunosuppression.” Calcineurin inhibition and related vascular/endothelial effects occur in nonimmune tissues, particularly the kidney, vasculature, and nervous system.

Important toxic mechanisms include:

Renal arteriolar vasoconstriction → ↓ renal blood flow/GFR → acute nephrotoxicity

Endothelial dysfunction + sodium retention + altered vasoactive mediators → hypertension

Tubular dysfunction → hyperkalemia + hypomagnesemia

Cerebral endothelial dysfunction + hypertension → encephalopathy/PRES

Chronic vascular/interstitial injury → arteriolopathy + striped tubulointerstitial fibrosis

Acute nephrotoxicity is often functional and reversible when exposure is reduced, while long-term high exposure can produce structural renal damage.

Acute Versus Chronic Toxicity

Acute and chronic cyclosporine toxicity behave differently.

A single oral overdose frequently causes only transient gastrointestinal or neurologic symptoms and modest renal dysfunction, even when the reported dose is very large.

By contrast, repeated excessive dosing or sustained high concentrations can cause progressive nephrotoxicity, hypertension, electrolyte abnormalities, neurotoxicity, and hepatotoxicity.

Accidental intravenous overdose is substantially more dangerous, because it bypasses variable GI absorption and can produce very high systemic exposure rapidly.

Toxic Dose

There is no reliable universal toxic dose.

Current Sandimmune prescribing information reports that oral doses as large as 10 g, approximately 150 mg/kg, have been associated mainly with vomiting, drowsiness, headache, tachycardia, and in some patients moderately severe but reversible renal impairment.

This means the old statement that “several grams have not produced toxicity” is partly true but potentially misleading:

Large acute oral ingestions may be relatively benign, but serious toxicity is still possible.

Severe neurotoxicity, nephrotoxicity, and hepatotoxicity have been reported after dosing errors, and fatal neurologic toxicity has occurred after massive IV overdose.

Dose alone should therefore never replace clinical assessment and therapeutic drug monitoring.

Intravenous Overdose

Parenteral overdose is more concerning than oral overdose.

Current labeling notes serious intoxication after accidental parenteral overdose, particularly in premature neonates.

A published adult case involving an IV infusion approximately ten times the intended rate developed massive cerebral edema and fatal brainstem compression; the estimated cyclosporine concentration may have approached approximately 1700 ng/mL.

Thus:

IV cyclosporine dosing errors should be treated as potentially severe even before symptoms develop.

Blood Concentrations – Important Unit Correction

The older chapter gives therapeutic cyclosporine concentrations in mg/mL. This is incorrect by roughly six orders of magnitude.

Modern cyclosporine concentrations are typically reported in:

ng/mL

not mg/mL.

For example, a trough might be reported as 100–300 ng/mL, not 100–300 mg/mL.

This is an important medication-safety correction.

Therapeutic Drug Monitoring

Cyclosporine has substantial interpatient and intrapatient pharmacokinetic variability, making therapeutic drug monitoring (TDM) essential during systemic therapy.

Monitoring usually uses whole blood, not plasma, because cyclosporine distributes substantially into erythrocytes and plasma measurements are temperature- and processing-dependent.

Two monitoring strategies are commonly used:

C0 = predose trough concentration

C2 = concentration approximately 2 hours after oral dosing

C2 may better reflect early drug exposure/AUC with modified formulations, although many centers continue to use C0 monitoring.

There Is No Universal Therapeutic or Toxic Level

The historical claim that the “therapeutic trough is 50–300” and toxicity develops “above 500” is too simplistic.

Cyclosporine target concentrations vary substantially according to:

• Transplanted organ
• Time since transplantation
• Immunologic risk
• Concomitant immunosuppression
• Assay technique
• Whether C0 or C2 is measured
• Nontransplant indication

There is no universally valid blood concentration above which toxicity always occurs.

Some patients develop toxicity at concentrations considered acceptable, while others tolerate substantially higher concentrations. In psoriasis trials, blood concentrations did not correlate reliably with either efficacy or renal dysfunction.

Therefore:

A cyclosporine concentration must be interpreted in clinical context—not as a stand-alone toxicity threshold.

Acute Overdose Concentrations

Markedly elevated levels can support the diagnosis after overdose.

A 2021 kidney-transplant medication error produced gastrointestinal and neurologic symptoms with a whole-blood concentration of 693 ng/mL.

A published prolonged overdose produced a trough concentration of 5877 ng/mL, accompanied by abdominal symptoms and renal dysfunction; recovery occurred after cyclosporine was discontinued.

A 2026 pediatric report described a child with a concentration around 1003 ng/mL after acute overdose who remained clinically stable apart from transient gastrointestinal effects, again illustrating that the number alone does not determine severity.

Pharmacokinetic Interactions

Cyclosporine is extensively metabolized by CYP3A4 and is a substrate of P-glycoprotein.

Consequently, inhibition of CYP3A4/P-gp can markedly increase cyclosporine exposure, while induction can markedly decrease exposure and risk graft rejection.

This makes drug interactions one of the most common modern pathways to toxicity.

Drugs That Increase Cyclosporine Concentrations

Clinically important inhibitors or interacting drugs include:

Clarithromycin, erythromycin, azole antifungals such as fluconazole/itraconazole/ketoconazole/voriconazole, diltiazem, verapamil, nicardipine, amiodarone, protease inhibitors, danazol, imatinib, metoclopramide, and others.

The medication list should therefore be reviewed carefully whenever a patient develops otherwise unexplained nephrotoxicity or neurotoxicity.

Grapefruit

Grapefruit and grapefruit juice should be avoided.

They can inhibit intestinal CYP3A activity and increase cyclosporine exposure. Current labeling specifically advises avoidance.

Drugs That Lower Cyclosporine Concentrations

Important enzyme-inducing drugs include:

Rifampin, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, nafcillin, and St. John’s wort.

These can reduce cyclosporine concentrations and potentially precipitate transplant rejection. Current labeling specifically warns that St. John’s wort has caused subtherapeutic concentrations, rejection, and graft loss.

Thus, reducing cyclosporine concentrations is not automatically beneficial even in a toxicity situation, particularly in a transplant recipient.

Cyclosporine as an Interaction Perpetrator

Cyclosporine does not merely have its own concentration altered by other drugs. It also inhibits CYP3A4, P-glycoprotein, and other transport systems, thereby increasing concentrations of many coadministered medications.

Examples include:

• Digoxin
• Colchicine
• Statins
• Dabigatran
• Repaglinide
• Sirolimus
• Some other narrow-therapeutic-index drugs

Colchicine Interaction

Cyclosporine can markedly increase colchicine exposure and the risk of myopathy, neuropathy, rhabdomyolysis, and multiorgan colchicine toxicity, particularly in renal dysfunction.

This interaction is clinically important because gout is common among transplant and CKD patients.

Statin Interaction

Cyclosporine increases exposure to several statins and markedly increases the risk of myopathy and rhabdomyolysis.

Current labeling reports myotoxicity with combinations involving lovastatin, simvastatin, atorvastatin, pravastatin, and, less commonly, fluvastatin. Statin selection and dosing therefore require careful attention to the individual statin’s labeling.

Muscle weakness or elevated CK in a patient receiving cyclosporine plus a statin should not automatically be attributed to the transplant illness itself.

Additive Nephrotoxicity

Cyclosporine nephrotoxicity can be amplified by other nephrotoxic agents, including aminoglycosides, vancomycin, amphotericin B, trimethoprim-sulfamethoxazole, NSAIDs, tacrolimus, methotrexate, and others.

Volume depletion further increases risk.

Thus, rising creatinine in a patient taking cyclosporine may represent:

high cyclosporine exposure + dehydration + another nephrotoxin

rather than a single cause.

Clinical Features of Acute Oral Overdose

Acute oral overdose commonly causes nausea, vomiting, abdominal discomfort, drowsiness, headache, tremor, flushing, tachycardia, and occasionally hypertension.

Moderate transient creatinine elevation may occur.

Serious toxicity is uncommon after a single isolated oral ingestion but cannot be excluded, especially after massive exposure or in patients with impaired metabolism.

Nephrotoxicity

The kidney is the principal target organ of cyclosporine toxicity.

Acute cyclosporine nephrotoxicity is largely related to renal vasoconstriction and decreased renal blood flow/GFR. It may manifest as an otherwise unexplained increase in serum creatinine and BUN, sometimes accompanied by hypertension and electrolyte abnormalities.

Early acute nephrotoxicity is often reversible after dose reduction or discontinuation.

Chronic Nephrotoxicity

Prolonged cyclosporine exposure can produce progressive structural renal damage characterized by arteriolopathy, tubular atrophy, and striped interstitial fibrosis.

Unlike acute functional vasoconstriction, advanced chronic nephrotoxicity may not fully reverse when the drug is stopped.

In a transplant recipient, distinguishing cyclosporine nephrotoxicity from graft rejection can be difficult, and both can occur simultaneously.

Hyperkalemia

Cyclosporine may produce clinically important hyperkalemia, sometimes accompanied by a hyperchloremic metabolic acidosis.

Potassium should therefore be monitored closely during suspected toxicity.

Current labeling discourages use of potassium-sparing diuretics with cyclosporine and urges caution with ACE inhibitors, ARBs, potassium-containing medications, and potassium-rich diets because of additive hyperkalemia risk.

Hypomagnesemia

Cyclosporine can promote renal magnesium loss and hypomagnesemia.

This is particularly relevant in neurotoxicity because hypomagnesemia has been identified as one of several risk factors associated with cyclosporine-related seizures and encephalopathy.

Correct clinically significant magnesium deficiency.

Hyperuricemia

Hyperuricemia can develop during calcineurin-inhibitor therapy and contributes to the high frequency of gout in transplant recipients.

It is generally a chronic therapeutic adverse effect rather than a major acute-overdose manifestation.

Hypertension

Hypertension is one of the most common cyclosporine adverse effects.

Mechanisms include systemic and renal vasoconstriction, sodium retention, sympathetic effects, and altered endothelial mediators.

Significant hypertension can contribute to neurologic toxicity, including PRES.

In toxicity, management begins by reducing or withholding cyclosporine when clinically appropriate and treating blood pressure according to contemporary hypertension/emergency principles.

Treatment of Cyclosporine-Associated Hypertension

The older recommendation that nifedipine is uniquely preferred because it is renoprotective is too narrow.

Dihydropyridine calcium-channel blockers can be useful, but antihypertensive therapy should be individualized. Some calcium-channel blockers—particularly diltiazem and verapamil—can raise cyclosporine concentrations through metabolic inhibition.

Nifedipine can also exacerbate cyclosporine-associated gingival hyperplasia.

For severe hypertensive emergency, use standard titratable IV antihypertensives according to the clinical situation rather than relying on one specific oral agent.

Neurologic Toxicity

Cyclosporine neurotoxicity ranges from mild to severe.

Mild manifestations include:

• Tremor
• Headache
• Paresthesias
• Dizziness
• Confusion

Severe manifestations include:

• Altered consciousness
• Seizures
• Visual disturbances
• Cortical blindness
• Motor abnormalities
• Psychiatric symptoms
• Encephalopathy
• PRES

Current labeling specifically recognizes posterior reversible encephalopathy syndrome (PRES) as a cyclosporine complication.

Posterior Reversible Encephalopathy Syndrome

PRES should be suspected when a patient receiving cyclosporine develops:

Hypertension + headache + seizures + confusion/encephalopathy + visual disturbance

MRI typically demonstrates posterior-predominant vasogenic edema, although distribution can be more widespread.

Risk factors described with cyclosporine include hypertension, hypomagnesemia, high drug concentrations, high-dose corticosteroid therapy, and graft-versus-host disease.

Treatment consists of:

• Reducing or stopping cyclosporine
• Controlling blood pressure
• Correcting magnesium and other metabolic abnormalities
• Treating seizures
• MRI/neurocritical-care assessment when severe

Most cases improve after appropriate management, although severe complications can occur.

Seizures

Seizures may occur with cyclosporine neurotoxicity and have particularly been reported when cyclosporine is combined with high-dose methylprednisolone.

Treat seizures with standard benzodiazepine-based therapy while correcting hypertension, hypomagnesemia, and excessive cyclosporine exposure.

Routine use of phenytoin solely because the patient has cyclosporine toxicity is undesirable because phenytoin strongly induces CYP3A metabolism and can complicate subsequent immunosuppressant dosing.

Hepatic Toxicity

Cyclosporine can cause hyperbilirubinemia, cholestatic or hepatocellular injury, hepatitis, and rarely liver failure.

Current labeling notes that hepatotoxicity usually improves after dose reduction.

Serial bilirubin and liver enzymes should therefore be monitored after significant overdose or sustained supratherapeutic exposure.

Thrombotic Microangiopathy

Cyclosporine can rarely contribute to thrombotic microangiopathy, producing thrombocytopenia and microangiopathic hemolytic anemia with organ dysfunction.

Current labeling recognizes a syndrome of thrombocytopenia and microangiopathic hemolytic anemia associated with cyclosporine.

If anemia and thrombocytopenia develop, obtain a smear, LDH, bilirubin, haptoglobin, renal studies, and other appropriate TMA testing rather than assuming the abnormalities are simple marrow suppression.

Hematologic Effects

The old description suggesting that cyclosporine routinely causes a decreased WBC count, decreased platelets, and elevated hematocrit as a typical toxicity syndrome is misleading.

Cyclosporine does not characteristically produce the predictable bone-marrow suppression seen with cytotoxic chemotherapy. Cytopenias should prompt evaluation for:

• Infection
• Other immunosuppressants
• TMA
• Bone-marrow disease
• Graft-related complications

Gingival Hyperplasia

Gingival overgrowth is a classic chronic adverse effect, particularly when cyclosporine is combined with nifedipine.

This is not a sign of acute poisoning.

Hypertrichosis

Hypertrichosis is another classic chronic cyclosporine adverse effect and can help identify long-term therapy, but it does not indicate acute toxicity severity.

Infection Risk

Cyclosporine’s therapeutic immunosuppression increases susceptibility to opportunistic and serious infections.

Current labeling describes potentially serious viral complications such as JC-virus-associated progressive multifocal leukoencephalopathy and BK/polyomavirus-associated nephropathy in immunosuppressed patients.

In a chronically treated transplant patient presenting with confusion or renal deterioration, drug toxicity should therefore be considered alongside opportunistic infection and graft-related disease.

Malignancy Risk

Long-term immunosuppression increases the risk of lymphoma and other malignancies, particularly skin malignancies. The risk is related to the degree and duration of immunosuppression.

This is a chronic therapeutic complication rather than an acute-overdose problem.

Diagnosis

Acute cyclosporine toxicity is diagnosed from the combination of:

Exposure history + symptoms + blood concentration + renal/electrolyte abnormalities

In chronic therapy, diagnosis is more difficult because the same findings can result from infection, rejection, other nephrotoxins, hypertensive disease, or underlying transplant complications.

The exact medication formulation and recent interacting drugs are essential parts of the diagnostic history.

Laboratory Evaluation

For significant overdose or suspected chronic toxicity, obtain:

• Serum creatinine and BUN
• Sodium and potassium
• Magnesium
• Bicarbonate
• Glucose
• Liver enzymes and bilirubin
• CBC
• Cyclosporine whole-blood concentration
• Urinalysis

Additional tests should be guided by severity.

CK is appropriate when rhabdomyolysis is possible, particularly in a patient taking an interacting statin or colchicine.

Cyclosporine Concentration Timing

The timing of a cyclosporine concentration must be documented.

A “level” drawn:

• immediately after a dose,
• at random,
• at C0,
• or at C2

cannot be interpreted using the same target.

Therefore:

Never interpret a cyclosporine concentration without knowing when the last dose was given.

Neurologic Testing

MRI brain is preferred when PRES is suspected.

CT may be useful initially in an unstable patient or when hemorrhage must be excluded, but a normal CT does not exclude PRES.

Lumbar puncture should not be routine in cyclosporine toxicity; it is performed only when infection or another CNS diagnosis remains a concern after considering procedural safety.

Initial Treatment

There is no specific antidote.

For acute toxicity:

1. Stop cyclosporine temporarily
2. Assess airway, breathing, and circulation
3. Obtain ECG and vital signs
4. Check renal function, potassium, magnesium, liver function, and cyclosporine concentration
5. Identify formulation and interacting medications
6. Correct dehydration and metabolic abnormalities
7. Treat hypertension and neurologic complications

In transplant recipients, decisions about holding and restarting cyclosporine should involve the transplant team because excessive reduction in immunosuppression creates a competing risk of graft rejection.

Gastrointestinal Decontamination

Induced Emesis

Do not induce vomiting.

Although current product labeling still contains historical language stating that forced emesis may be useful after overdose, modern toxicology no longer recommends induced emesis as routine poisoning management.

The risks of aspiration and uncertain benefit outweigh its usefulness.

Gastric Lavage

Current Sandimmune labeling also retains historical language suggesting gastric lavage may be valuable within two hours because absorption is relatively slow.

This recommendation conflicts with modern general toxicology practice.

AACT/EAPCCT guidance states that gastric lavage should not be performed routinely, if at all, because outcome benefit has not been demonstrated and serious complications can occur.

Therefore:

Routine gastric lavage is obsolete for cyclosporine overdose.

Only an extraordinary, immediately life-threatening, very recent ingestion could justify consideration after expert toxicology consultation and airway protection.

Activated Charcoal

Single-dose activated charcoal may be considered after a recent substantial oral cyclosporine ingestion if the patient is alert with an intact airway or has a protected airway.

Activated charcoal has been reported in cyclosporine overdose, but there is no high-quality evidence that it improves clinical outcomes. General toxicology guidance states that charcoal is most likely to reduce absorption when given within approximately the first hour and should not be administered routinely.

Thus:

Activated charcoal is selective, not mandatory.

Multiple-dose charcoal is not an established cyclosporine elimination strategy.

IV Fluids

Patients with vomiting or volume depletion should receive appropriate isotonic crystalloid.

Avoid excessive fluid administration in transplant patients with impaired cardiac or renal function.

Correcting hypovolemia is important because dehydration can intensify calcineurin-inhibitor nephrotoxicity.

Treatment of AKI

Hold or reduce cyclosporine and discontinue avoidable nephrotoxins.

Correct volume depletion, electrolyte abnormalities, and hemodynamic disturbances.

Serially monitor:

• Creatinine
• Potassium
• Magnesium
• Urine output
• Acid-base status

Nephrology consultation is appropriate for severe or progressive AKI.

Hemodialysis

Cyclosporine is not effectively removed by hemodialysis.

Current prescribing information explicitly states that cyclosporine is not dialyzable to any significant extent and is also poorly cleared by charcoal hemoperfusion.

Hemodialysis should therefore not be initiated merely to eliminate cyclosporine.

It remains appropriate for standard indications such as:

• Refractory hyperkalemia
• Severe metabolic acidosis
• Pulmonary edema/volume overload
• Uremic complications
• Severe AKI requiring renal replacement

A published overdose case underwent hemodialysis because of acute renal failure, not because dialysis was expected to substantially clear cyclosporine.

Charcoal Hemoperfusion

Charcoal hemoperfusion does not reliably clear cyclosporine and is not recommended as routine enhanced elimination.

Plasma Exchange and Whole-Blood Exchange

There are case reports of whole-blood exchange and plasma exchange after exceptionally severe cyclosporine intoxication. One cardiac-transplant patient with severe nephrotoxicity, hepatotoxicity, and neurotoxicity recovered after erythrocytapheresis followed by plasma exchange.

However:

These procedures remain experimental rescue therapies, not standard care.

Evidence is limited to isolated cases.

CYP3A Enzyme Induction as Rescue Therapy

Because cyclosporine is metabolized by CYP3A, drugs such as phenobarbital, phenytoin, and rifampin have occasionally been deliberately used to accelerate elimination after severe supratherapeutic exposure.

A 2017 review found only a small number of case reports and concluded that routine use cannot be recommended.

A 2026 pediatric overdose report used rifampin and phenobarbital with rapid decline in cyclosporine concentration, but this remains case-level evidence.

The major danger is obvious:

CYP induction → cyclosporine concentration falls → prolonged under-immunosuppression → possible graft rejection

Rifampin induction can persist after the drug is stopped and has caused prolonged subtherapeutic cyclosporine concentrations.

Therefore:

Metabolic induction should be reserved for exceptional severe toxicity under transplant/toxicology/pharmacy guidance.

Hypertension Treatment

For mild-to-moderate cyclosporine-associated hypertension, reducing cyclosporine exposure may itself improve blood pressure.

When pharmacologic treatment is needed, choose antihypertensive agents based on the clinical situation while accounting for cyclosporine interactions.

Avoid automatically using:

• Potassium-sparing diuretics in hyperkalemia-prone patients
• Diltiazem or verapamil without recognizing that they may increase cyclosporine concentrations

Severe hypertension with neurologic symptoms should be treated as a hypertensive emergency.

Treatment of PRES

For suspected cyclosporine-associated PRES:

Hold/reduce cyclosporine → control severe hypertension → correct magnesium → treat seizures → obtain MRI → involve neurology/transplant specialists

PRES is often reversible when the cause is recognized early.

Hyperkalemia Treatment

Treat severe hyperkalemia using standard emergency measures:

• IV calcium for membrane stabilization when indicated
• Insulin plus glucose
• β₂-agonist therapy
• Bicarbonate when appropriate for significant metabolic acidosis
• Renal replacement for refractory cases

Simultaneously stop contributory potassium-retaining drugs when possible.

Hypomagnesemia Treatment

Replace magnesium when clinically significant, especially with:

• Seizures
• Ventricular dysrhythmias
• PRES/neurotoxicity
• Marked laboratory deficiency

Rhabdomyolysis

If rhabdomyolysis occurs, search for interacting drugs—especially statins or colchicine.

Stop implicated agents, provide appropriate crystalloid, and monitor CK, potassium, creatinine, calcium, and urine output.

Pregnancy

The old FDA Pregnancy Category C classification is obsolete.

Current Sandimmune labeling states that decades of human experience—including transplant registries, cohort studies, and case reports—have not identified a cyclosporine-associated increase in major congenital malformations or miscarriage. However, hypertension, preeclampsia, prematurity, and low birth weight are increased among cyclosporine-treated pregnant populations, although underlying disease and concomitant therapy make causality difficult to determine.

Therefore therapeutic cyclosporine may be continued during pregnancy when clinically necessary, particularly for transplant maintenance.

Acute maternal toxicity should be treated aggressively because maternal renal failure, severe hypertension, seizures, and hypoxia pose major fetal risks.

Breastfeeding

The historical implication that lactation should generally be avoided is outdated.

Current LactMed data indicate that a fully breastfed infant typically receives less than about 2% of the maternal weight-adjusted cyclosporine dose, often less than 1%. Most reported breastfed infants have undetectable blood cyclosporine concentrations, and published follow-up has not demonstrated adverse effects on growth, development, or renal function. Many professional guidelines consider cyclosporine compatible with breastfeeding with appropriate infant monitoring.

Current Sandimmune labeling likewise states that cyclosporine is present in human milk but that adverse effects in breastfed infants have not been reported.

Therapeutic breastfeeding data should not automatically be extrapolated to a mother with an acute massive overdose.

Ophthalmic Cyclosporine in Pregnancy/Lactation

Systemic absorption after ophthalmic cyclosporine is minimal. LactMed considers significant infant exposure unlikely, and punctal occlusion after eye-drop administration can further reduce systemic absorption.

Monitoring After Acute Overdose

Patients with a substantial ingestion should have serial assessment of:

• Mental status
• Blood pressure
• Heart rate
• Serum creatinine/BUN
• Potassium
• Magnesium
• Liver enzymes/bilirubin
• Cyclosporine concentration

The appropriate monitoring duration depends on formulation, amount, symptoms, concentration trend, renal function, and comorbidities.

The old rule simply to recheck “within a day or two” is inadequate for a symptomatic patient with marked overdose.

Monitoring During Chronic Therapy

Current systemic labeling emphasizes repeated monitoring of:

renal function, liver function, potassium, magnesium, lipids, and cyclosporine blood concentrations, especially in transplant patients.

Drug concentrations should also be reassessed whenever:

• An interacting medication is started or stopped
• Formulation is changed
• Graft dysfunction occurs
• Renal function deteriorates unexpectedly
• Neurotoxicity appears

Observation

A small isolated oral dosing error in an asymptomatic patient may require only clinical observation and follow-up testing after poison-center/transplant consultation.

Patients with:

• Significant intentional overdose
• Markedly elevated concentration
• AKI
• Hypertension
• Neurologic symptoms
• Significant electrolyte abnormalities
• IV overdose

require prolonged monitored evaluation.

There is no universally validated fixed “6-hour” discharge rule for cyclosporine overdose.

Admission

Hospital admission is appropriate for:

• Significant acute overdose with symptoms
• AKI
• Sustained hypertension
• Important hyperkalemia or hypomagnesemia
• Altered consciousness
• Tremor or progressive neurotoxicity
• Significant hepatotoxicity
• Substantial IV dosing error
• Inability to obtain reliable transplant follow-up

ICU admission is appropriate for:

• Seizures
• PRES
• Severe hypertensive emergency
• Coma
• Severe AKI with metabolic complications
• Hemodynamic instability
• Massive IV overdose

Discharge

Discharge requires:

• Stable mental status and vital signs
• Stable or improving renal function
• No significant electrolyte abnormality
• No progressive neurotoxicity
• A clearly declining/acceptable cyclosporine exposure pattern
• A safe plan for restarting or adjusting immunosuppression

For transplant recipients, discharge planning should include the transplant team because prolonged withholding of cyclosporine can create serious rejection risk.

Prognosis

Most isolated oral cyclosporine overdoses recover completely with drug withdrawal and supportive care.

Even doses approaching 10 g have produced relatively modest toxicity in many patients.

However, prognosis is worse when poisoning involves:

• Massive IV exposure
• Severe neurotoxicity/PRES
• Refractory hypertension
• Advanced AKI
• Significant hepatic dysfunction
• Prolonged repeated overdose
• Serious drug interactions

Chronic nephrotoxicity may leave persistent renal impairment even after cyclosporine is reduced or discontinued.

Important Pitfalls

A major pitfall is the historical concentration unit.

Cyclosporine levels are measured in ng/mL—not mg/mL.

A stated “500 mg/mL cyclosporine trough” would be physiologically implausible.

Another pitfall is assuming that a blood concentration above one arbitrary threshold proves toxicity. There is no universal toxic level, and therapeutic targets differ widely according to indication and timing.

Another major error is ignoring the exact formulation. Sandimmune and modified cyclosporine formulations such as Neoral are not bioequivalent or automatically interchangeable.

The most important modern source of toxicity is often drug interaction, particularly CYP3A4/P-gp inhibition.

Always ask about:

clarithromycin, erythromycin, azoles, diltiazem, verapamil, amiodarone, HIV antivirals, grapefruit, colchicine, statins, and additional nephrotoxins.

Another pitfall is interpreting rising creatinine in a transplant recipient as automatically due to rejection. Cyclosporine nephrotoxicity and rejection can look similar and may coexist.

Do not miss PRES in a cyclosporine-treated patient with hypertension, seizures, confusion, or visual symptoms.

The historical recommendation for gastric lavage and forced emesis should not be followed routinely. Modern toxicology discourages both; activated charcoal is selective rather than mandatory.

Another pitfall is ordering hemodialysis simply to clear cyclosporine.

Dialysis treats AKI complications—it does not effectively clear cyclosporine.

Finally, using rifampin, phenytoin, or phenobarbital to intentionally accelerate metabolism is not routine therapy. Evidence consists mainly of case reports, and prolonged enzyme induction may drive concentrations too low and endanger a transplanted organ.

High-Yield Toxicology Pearls

Cyclosporine toxicity is primarily a renal–vascular–neurologic syndrome.

Think:

AKI + hypertension + hyperkalemia/hypomagnesemia + tremor/encephalopathy

The mechanism is cyclophilin binding → calcineurin inhibition → reduced NFAT/IL-2 signaling, while toxicity reflects renal vasoconstriction, endothelial dysfunction, tubular effects, and CNS vascular injury.

A single oral overdose is often less toxic than expected. Current labeling reports oral doses up to 10 g (~150 mg/kg) producing mainly vomiting, drowsiness, headache, tachycardia, and reversible renal dysfunction in many patients.

However, IV overdose can be catastrophic and repeated excessive exposure can produce severe renal, hepatic, and neurologic toxicity.

Whole-blood concentrations are usually reported in ng/mL. Do not use the old mg/mL units.

There is no universal “toxic cyclosporine level.” Target concentrations vary by transplant type, time since transplantation, assay, and whether C0 or C2 monitoring is used.

Always establish the exact formulation:

Sandimmune and Neoral/modified cyclosporine are not automatically interchangeable.

Cyclosporine is a CYP3A4 and P-glycoprotein substrate. Clarithromycin, erythromycin, azole antifungals, diltiazem, verapamil, amiodarone, protease inhibitors, and grapefruit can raise concentrations.

Cyclosporine also raises concentrations of other drugs, notably colchicine and statins, increasing the risk of myopathy/rhabdomyolysis.

Acute nephrotoxicity is usually caused by renal vasoconstriction and reduced GFR and may improve after dose reduction. Chronic exposure can produce arteriolopathy and irreversible interstitial fibrosis.

Hypertension is common. Monitor potassium because hyperkalemia can occur, and monitor magnesium because hypomagnesemia may contribute to neurologic toxicity.

A patient receiving cyclosporine who develops:

Headache + hypertension + seizures + visual disturbance/confusion

should be evaluated urgently for PRES.

There is no antidote.

Activated charcoal can be considered after a recent substantial ingestion when the airway is safe, but routine lavage and induced emesis are obsolete.

Cyclosporine is not effectively removed by hemodialysis or charcoal hemoperfusion. Dialysis is reserved for conventional AKI/metabolic indications.

CYP enzyme induction with phenytoin, phenobarbital, or rifampin has been used in exceptional severe cases, but evidence is limited and routine use is not recommended because excessive reduction in immunosuppression can precipitate graft rejection.

Pregnancy Category C terminology is obsolete. Available human data have not demonstrated an increased rate of major congenital malformations or miscarriage, although prematurity, hypertension, preeclampsia, and low birth weight are more frequent in cyclosporine-treated transplant populations.

Therapeutic cyclosporine is increasingly regarded as compatible with breastfeeding with appropriate infant monitoring, with typical infant exposure well below the maternal weight-adjusted dose.

The most important clinical warning is:

In a patient taking cyclosporine, an unexplained rise in creatinine plus hypertension or tremor should trigger an immediate search for excessive drug exposure and a CYP3A4/P-gp interaction.

Toxicology – Cyclobenzaprine

Core Concept

Cyclobenzaprine is a centrally acting skeletal muscle relaxant with a tricyclic chemical structure closely related to amitriptyline. In overdose, its dominant effects are usually sedation and antimuscarinic toxicity, particularly drowsiness, sinus tachycardia, agitation, confusion, dry mucosae, mydriasis, and urinary retention.

A useful toxicologic sequence is:

Cyclobenzaprine → central sedation + muscarinic antagonism → drowsiness/confusion + tachycardia + dry skin/mouth + mydriasis + urinary retention

Severe poisoning can additionally produce coma, seizures, hypotension, respiratory depression, QRS widening, and ventricular dysrhythmias, but important modern poison-center series show that cyclobenzaprine is considerably less cardiotoxic than classic tricyclic antidepressants in most isolated overdoses.

The major bedside principle is:

Cyclobenzaprine looks chemically like a TCA, but most isolated overdoses behave primarily as sedative-antimuscarinic poisoning rather than classic severe TCA cardiotoxicity.

Nevertheless, an ECG is essential because the rare patient who develops QRS widening or ventricular dysrhythmia should be treated as having sodium-channel blockade.

Current Forms and Uses

Cyclobenzaprine is used as an adjunct to rest and physical therapy for short-term relief of muscle spasm associated with acute painful musculoskeletal conditions. It is not considered effective for spasticity caused by cerebral or spinal-cord disease. Current labeling recommends limiting treatment to approximately 2–3 weeks because evidence for prolonged use is inadequate.

Immediate-release tablets are currently available in strengths including 5 mg, 7.5 mg, and 10 mg. The usual adult immediate-release dose is:

5 mg orally three times daily

which may be increased to 7.5–10 mg three times daily according to response. The old statement that 10 mg three times daily is simply the “usual dose” therefore overstates current starting therapy.

Extended-release formulations are also available as 15-mg and 30-mg capsules, generally administered once daily.

Pharmacology

Cyclobenzaprine acts predominantly in the central nervous system, particularly at brainstem motor pathways, reducing tonic somatic motor activity. It does not act directly at the neuromuscular junction and is not a peripheral skeletal-muscle paralytic.

Its pharmacologic profile includes:

Central sedation + antimuscarinic activity + alpha-adrenergic effects + monoaminergic activity

These actions explain the mixture of somnolence, anticholinergic findings, sinus tachycardia, occasional hypotension, and serotonergic drug interactions.

Relationship to Tricyclic Antidepressants

Cyclobenzaprine is structurally related to amitriptyline and imipramine, and older toxicology texts therefore often approached overdose as if it were essentially TCA poisoning.

That comparison is useful—but incomplete.

Two large poison-center studies demonstrate an important difference. A multicenter review of 402 isolated cyclobenzaprine ingestions found no deaths, no seizures, and no life-threatening dysrhythmias; common effects were lethargy, sinus tachycardia, and agitation. Doses ranged up to 1000 mg.

A later review of 209 isolated acute overdoses similarly found no deaths, no wide-QRS cases, and no ventricular dysrhythmias attributable to cyclobenzaprine. Hypotension was uncommon.

Thus:

Do not assume that every cyclobenzaprine overdose will behave like amitriptyline.

However, rare severe cardiotoxic cases and fatalities have been reported, and current FDA labeling continues to regard QRS widening, dysrhythmia, severe hypotension, seizures, and cardiac arrest as possible critical manifestations.

Mechanism of Toxicity

The most common toxicity reflects central nervous system depression and muscarinic receptor antagonism.

Antimuscarinic effects produce:

Mydriasis + dry mouth + dry/flushed skin + tachycardia + decreased bowel motility + urinary retention + delirium

At very large concentrations, cyclobenzaprine may also interfere with cardiac sodium conduction in a TCA-like manner. Clinically significant sodium-channel blockade is uncommon in isolated poisoning but should be suspected when the ECG demonstrates QRS widening, terminal conduction abnormalities, ventricular dysrhythmia, or severe hypotension.

Pharmacokinetics

Cyclobenzaprine is relatively slowly eliminated. Current immediate-release labeling reports an effective half-life of approximately 18 hours, with a wide range of about 8–37 hours. It is highly protein bound and undergoes extensive hepatic metabolism, including metabolism through CYP3A4, CYP1A2, and to a lesser extent CYP2D6.

Repeated three-times-daily dosing results in accumulation, with steady state reached after several days. Plasma concentrations are higher in older adults and patients with hepatic impairment.

The long half-life helps explain why symptomatic patients may remain sedated or anticholinergic well beyond the initial emergency-department period.

Toxic Dose

There is no precisely defined toxic or fatal dose.

Older statements that “several hundred milligrams may cause death” are too simplistic. Fatal cases exist, but large isolated overdoses are often survivable with supportive care.

In the classic multicenter poison-center study, doses ranged from 5 to 1000 mg. No deaths occurred, and no patient developed life-threatening cardiovascular or neurologic toxicity. No effects requiring treatment beyond gastrointestinal decontamination were reported below 100 mg in that series.

This should not be converted into a rigid “safe dose” rule. Patient age, formulation, coingestants, cardiovascular disease, serotonergic drugs, and uncertainty in the reported amount all matter.

Therefore:

Dose helps with risk assessment, but the ECG and clinical syndrome determine management.

Risk Factors for Severe Toxicity

Risk is increased by large intentional ingestion, extended-release formulations, alcohol or sedative coingestion, serotonergic coingestants, advanced age, hepatic impairment, and underlying cardiac conduction disease.

Current labeling specifically recognizes higher cyclobenzaprine concentrations in elderly patients and patients with hepatic impairment.

Extended-release labeling advises against use in moderate-to-severe hepatic impairment and recommends caution regarding the drug’s anticholinergic and sedating properties.

Drug Interactions

Cyclobenzaprine potentiates the effects of alcohol, barbiturates, opioids, benzodiazepines, and other CNS depressants. Coingestion can convert an otherwise moderate cyclobenzaprine overdose into clinically important respiratory depression or coma.

An important modern addition is its interaction with serotonergic medications.

Serotonin Syndrome

Cyclobenzaprine has serotonergic pharmacology and has been associated with serotonin syndrome, particularly when combined with other serotonergic drugs.

Reported interacting agents include:

SSRIs, SNRIs, TCAs, tramadol, meperidine, bupropion, and MAO inhibitors, among others. Current labeling specifically warns about this potentially life-threatening interaction.

The clinical syndrome includes:

Agitation/confusion + diaphoresis + hyperthermia + autonomic instability + tremor + hyperreflexia + clonus ± rigidity

This differs from uncomplicated antimuscarinic delirium, in which the skin and mucosa are characteristically dry and clonus/hyperreflexia are not typical.

Monoamine Oxidase Inhibitors

Cyclobenzaprine is contraindicated during treatment with an MAO inhibitor and for 14 days after MAOI discontinuation. Hyperpyretic reactions, seizures, and deaths have been reported with cyclobenzaprine or closely related tricyclic drugs in this setting.

Therefore:

Cyclobenzaprine + MAOI is a major interaction, not merely additive sedation.

Clinical Features

The typical isolated overdose produces:

Drowsiness + sinus tachycardia ± antimuscarinic findings

Current labeling identifies drowsiness and tachycardia as the most common manifestations of overdose. Less frequent findings include tremor, agitation, ataxia, confusion, hallucinations, hypertension, vomiting, and coma. Rare severe manifestations include cardiac arrest, dysrhythmias, severe hypotension, seizures, and neuroleptic-malignant-syndrome-like presentations.

Central Nervous System

Sedation is common and may range from mild drowsiness to significant somnolence. Patients can also develop agitation, confusion, hallucinations, dysarthria, ataxia, or delirium.

This apparent mixture of sedation and agitation is typical of drugs with both central sedative and antimuscarinic activity.

Coma is unusual in uncomplicated moderate isolated overdose and should prompt careful consideration of:

opioids, ethanol, benzodiazepines, sedative-hypnotics, hypoglycemia, trauma, seizures, or another coingestant.

Antimuscarinic Syndrome

Characteristic findings include:

Mydriasis, blurred vision, dry mouth, warm/dry skin, sinus tachycardia, urinary retention, decreased bowel sounds, agitation, hallucinations, and delirium.

Severe ileus and urinary retention are possible but uncommon.

Hyperthermia can result when reduced sweating combines with severe agitation.

Cardiovascular Effects

Sinus tachycardia is by far the most frequent cardiovascular abnormality and usually reflects antimuscarinic activity.

Mild hypertension may occur. Hypotension is less frequent and can result from vasodilation, severe CNS depression, dehydration, or rare myocardial/conduction toxicity.

Life-threatening ventricular dysrhythmias are uncommon in isolated cyclobenzaprine overdose, which distinguishes it from classic TCA poisoning.

Nevertheless, current labeling considers changes in QRS width or axis clinically significant markers of severe toxicity.

Respiratory Toxicity

Respiratory depression can occur from severe CNS depression, particularly after large overdose or coingestion of alcohol, opioids, benzodiazepines, or other sedatives.

Patients with declining mental status require close airway assessment.

Respiratory failure in a presumed cyclobenzaprine overdose should trigger strong consideration of an opioid or other sedative coingestant.

Seizures

Seizures are rare after isolated cyclobenzaprine overdose. In one large series of 402 isolated ingestions, no seizures occurred; another poison-center study found reported seizure events were not attributable to cyclobenzaprine itself.

Nevertheless, seizures remain described in postmarketing overdose reports and are plausible in severe poisoning or mixed ingestion.

Treat seizures with benzodiazepines first-line.

Gastrointestinal Effects

Nausea and vomiting can occur. Antimuscarinic effects may slow gastrointestinal motility and produce constipation or ileus.

Delayed gastric emptying is theoretically relevant after very large ingestions, although routine prolonged gastrointestinal decontamination is not supported.

Genitourinary Effects

Urinary retention is a classic antimuscarinic effect and may require bladder assessment or temporary catheterization when severe.

Patients with prostatic obstruction or other baseline voiding problems may be more susceptible.

Rhabdomyolysis

Rhabdomyolysis is uncommon but may develop after prolonged agitation, seizures, hyperthermia, or prolonged immobilization.

Check CK, potassium, renal function, and urinalysis in patients with those risk factors.

Diagnosis

Diagnosis is primarily clinical and based on history, medication access, physical findings, and ECG.

A characteristic presentation is:

Cyclobenzaprine exposure → drowsiness/tachycardia → dry antimuscarinic findings ± delirium

Because overdose frequently occurs in deliberate self-poisoning, clinicians should actively search for coingestants.

Differential Diagnosis

Important toxicologic alternatives include:

Tricyclic antidepressants, diphenhydramine and other antihistamines, antipsychotics, ethanol, opioids, benzodiazepines, sedative-hypnotics, serotonin syndrome, and sympathomimetic poisoning.

TCA poisoning is particularly important because QRS widening and severe cardiotoxicity require immediate sodium bicarbonate treatment.

Serotonin syndrome can overlap with cyclobenzaprine toxicity but is suggested by clonus, hyperreflexia, diaphoresis, increased bowel activity, and serotonergic coexposure rather than a purely dry antimuscarinic syndrome.

Initial Assessment

Begin with airway, breathing, circulation, bedside glucose, temperature, neurologic examination, and a careful medication history.

In unexplained respiratory depression, naloxone should be given when opioid toxicity is plausible. Naloxone does not reverse cyclobenzaprine itself.

Routine “coma cocktail” administration of thiamine or glucose to every patient is obsolete; glucose should be measured and hypoglycemia treated when present, while thiamine is used when clinically indicated.

ECG

Obtain an ECG after a significant cyclobenzaprine overdose.

Current labeling identifies QRS abnormalities as important markers of severe toxicity.

Assess:

heart rate, rhythm, PR interval, QRS duration, QT/QTc, and evidence of sodium-channel blockade.

A normal ECG strongly reduces concern for major TCA-like cardiotoxicity but does not replace clinical observation.

QRS Widening

A QRS duration of approximately ≥100 ms is traditionally regarded as concerning in this setting, consistent with current product labeling.

However, the key concept is not the exact number in isolation:

Cyclobenzaprine overdose + new QRS widening, ventricular dysrhythmia, or conduction-related hypotension = treat for sodium-channel blockade.

Laboratory Testing

Asymptomatic low-risk patients generally do not require extensive laboratory testing.

In symptomatic or intentional overdose, useful studies include:

glucose, electrolytes, renal function, and an acetaminophen concentration when the ingestion history is uncertain.

Additional tests should be targeted to the clinical picture. CK is appropriate after seizures, prolonged agitation, hyperthermia, or prolonged unconsciousness.

Blood gas and lactate can help when severe hypotension, seizures, respiratory failure, or major conduction abnormalities are present.

Cyclobenzaprine Levels

Serum cyclobenzaprine concentrations do not guide acute management.

Current labeling specifically advises against using plasma drug levels to direct overdose care.

Clinical status and ECG findings are more useful.

Initial Treatment

Treatment is primarily supportive.

Provide airway support, oxygen when indicated, IV access, cardiac monitoring for significant exposures, treatment of agitation or seizures, management of hypotension, and correction of hyperthermia or metabolic abnormalities.

A poison center or medical toxicologist should be consulted for severe or unusual toxicity, especially QRS widening, dysrhythmia, seizures, refractory delirium, or significant extended-release overdose.

Airway Management

Patients with severe CNS depression should be positioned and monitored carefully for aspiration and hypoventilation.

Endotracheal intubation is appropriate for:

loss of airway reflexes, persistent hypoventilation, profound coma, recurrent seizures, or inability to manage secretions.

Current product labeling warns that severe CNS depression can deteriorate abruptly.

Activated Charcoal

A single dose of activated charcoal may be considered after a recent substantial ingestion if the airway is intact or protected.

Modern toxicology guidance does not recommend activated charcoal routinely for every poisoned patient. Its greatest potential benefit is during approximately the first hour after ingestion, and it is contraindicated when the airway is unprotected.

Because cyclobenzaprine has antimuscarinic effects that may delay gastric emptying, occasional later use might be considered after a very large ingestion in consultation with toxicology, but evidence for improved clinical outcomes is lacking.

Gastric Lavage

The current cyclobenzaprine package insert still contains old language recommending large-volume gastric lavage after overdose.

That recommendation is not consistent with modern general toxicology practice.

AACT/EAPCCT guidance concludes that gastric lavage should not be performed routinely, if at all, because evidence for clinical benefit is poor and complications can be serious.

Therefore:

Routine gastric lavage is obsolete for cyclobenzaprine overdose.

Only an extraordinary, immediately life-threatening ingestion presenting extremely early could justify considering it after expert toxicology consultation and airway protection.

Do Not Induce Vomiting

Ipecac or other induced emesis has no role.

Cyclobenzaprine can cause sedation abruptly, increasing aspiration risk.

Sodium Bicarbonate

Cyclobenzaprine ordinarily does not require sodium bicarbonate merely because it resembles a TCA.

However, if there is evidence of cardiac sodium-channel blockade—particularly:

QRS widening + ventricular dysrhythmia ± severe conduction-related hypotension

then treat with IV sodium bicarbonate.

A reasonable toxicology regimen is:

Sodium bicarbonate 1–2 mEq/kg IV bolus

repeated according to ECG and hemodynamic response, followed when necessary by an alkalinizing infusion.

Current labeling recommends alkalinization when dysrhythmia or QRS widening occurs and identifies a target blood pH around 7.45–7.55, while avoiding excessive alkalemia.

The therapeutic endpoint is improvement in QRS duration, rhythm, and blood pressure, not attainment of a bicarbonate concentration.

Dysrhythmias

Correct oxygenation, acidemia, and electrolyte abnormalities first.

Sodium bicarbonate is first-line when sodium-channel blockade is suspected.

If ventricular dysrhythmia persists despite adequate bicarbonate therapy, lidocaine can be considered after toxicology consultation.

The product label still mentions bretylium and phenytoin as possible therapies, but bretylium is essentially obsolete in contemporary practice, and phenytoin is not a preferred treatment for toxicologic sodium-channel cardiotoxicity or drug-induced seizures.

Avoid class IA and IC sodium-channel-blocking antiarrhythmics such as procainamide and flecainide because they may worsen conduction toxicity.

Hypotension

Give isotonic crystalloid when volume depletion is present.

If clinically important hypotension persists despite appropriate fluids:

Norepinephrine is a reasonable first-line vasopressor.

The historical dopamine-first strategy and routine Trendelenburg positioning are outdated.

Persistent hypotension associated with QRS widening should also prompt immediate sodium bicarbonate therapy because myocardial sodium-channel blockade may be contributing.

Agitation

Mild antimuscarinic agitation can often be managed with environmental control and observation.

For significant agitation, benzodiazepines are reasonable, particularly when the diagnosis is uncertain, seizures are a concern, or serotonin syndrome cannot be excluded.

Excessive benzodiazepine administration should be avoided because cyclobenzaprine already produces sedation and may increase the likelihood of respiratory compromise.

Physostigmine – Important Modern Nuance

The old chapter recommends physostigmine 1–2 mg IV diagnostically for cyclobenzaprine-associated anticholinergic syndrome.

That is too liberal.

Physostigmine can be highly effective for severe pure antimuscarinic delirium, and modern evidence suggests it is safer than its historical reputation when appropriately selected. However, significant adverse effects are more concerning in patients with QRS prolongation or exposure to drugs capable of sodium-channel blockade. A large literature review concluded that physostigmine should be avoided when the ECG demonstrates QRS prolongation.

Cyclobenzaprine is structurally TCA-like and has at least theoretical and label-recognized potential for sodium-channel toxicity.

Therefore:

Physostigmine is not routine treatment for cyclobenzaprine overdose.

It may be considered only for severe, clearly antimuscarinic delirium when:

• the ECG is reassuring,
• QRS is not widened,
• no important TCA or other sodium-channel blocker is suspected,
• there is no significant bradycardia or conduction disease,
• and a medical toxicologist or poison center supports its use.

Current cyclobenzaprine labeling itself recommends against physostigmine except in exceptional severe cases after consultation with a poison center.

Serotonin Syndrome Treatment

If serotonin syndrome develops, stop cyclobenzaprine and other serotonergic drugs.

Treatment is primarily:

sedation with benzodiazepines + IV fluids + active cooling for significant hyperthermia + management of autonomic instability.

Severe hyperthermia from muscle activity requires aggressive sedation and external cooling. Antipyretics do not treat the mechanism.

Cyproheptadine may be considered in persistent moderate-to-severe serotonin toxicity when enteral administration is possible, but supportive care remains the priority.

Seizure Treatment

Use benzodiazepines first-line.

Refractory seizures can be treated with additional GABAergic therapy such as phenobarbital or propofol according to severity.

Phenytoin is generally a poor choice for toxin-induced seizures and is not preferred despite its appearance in older cyclobenzaprine labeling.

Hyperthermia

Hyperthermia can arise from antimuscarinic impairment of sweating, agitation, seizures, or serotonin toxicity.

Treatment is:

sedation + removal of excess clothing + active external cooling + IV fluids as appropriate.

Severe hyperthermia requires rapid control because rhabdomyolysis, AKI, coagulopathy, and neurologic injury can develop.

Rhabdomyolysis

Treat with appropriate IV crystalloid and management of the precipitating cause, especially seizures, agitation, or hyperthermia.

Follow CK, potassium, creatinine, and urine output.

Routine bicarbonate alkalinization of the urine is not required solely because rhabdomyolysis is present.

Enhanced Elimination

Hemodialysis does not have a meaningful role in cyclobenzaprine clearance.

Cyclobenzaprine is highly protein bound, extensively distributed, and present at relatively low plasma concentrations. Current labeling states dialysis is probably of no value.

Hemoperfusion, forced diuresis, and urinary manipulation are likewise not established therapies.

Antidote

There is no specific antidote for cyclobenzaprine poisoning.

Physostigmine is an antidote to selected antimuscarinic delirium, not a specific cyclobenzaprine antidote and not a treatment for sodium-channel toxicity.

Monitoring

Symptomatic patients should receive serial neurologic examinations and appropriate respiratory monitoring.

Significant overdose warrants continuous ECG monitoring until:

mental status is improving, vital signs are stable, and there is no evolving conduction abnormality.

Repeat the ECG if tachycardia worsens, hypotension develops, seizures occur, or mental status deteriorates.

Observation Period

The older fixed 6-hour rule is useful only as a rough minimum for immediate-release exposures.

In the classic multicenter poison-center series, all patients with a known ingestion time who eventually became symptomatic did so within approximately 4 hours.

Thus, an asymptomatic patient after an uncomplicated immediate-release ingestion who has a normal ECG and remains completely well through an adequate observation interval—commonly around 6 hours—may often be medically cleared.

However, observation should be longer for:

extended-release formulations, very large or uncertain ingestions, significant coingestants, abnormal ECG, evolving anticholinergic findings, older adults, or hepatic impairment.

Admission

Hospital admission is appropriate for patients with:

persistent altered mental status, significant agitation, recurrent vomiting with aspiration risk, hypotension, seizures, respiratory depression, urinary retention requiring treatment, significant serotonin toxicity, or ECG abnormalities.

ICU-level care is appropriate for:

coma requiring ventilation, seizures, severe hyperthermia, QRS widening, ventricular dysrhythmia, severe hypotension, or multiorgan complications.

Discharge

A patient may be discharged when:

mental status has returned to baseline, vital signs are stable, the ECG is reassuring, ambulation is safe, oral intake is adequate, and no delayed toxicity is expected from the formulation or coingestants.

Intentional ingestion requires appropriate psychiatric and safety assessment after medical stabilization.

Prognosis

Most isolated cyclobenzaprine overdoses have a favorable prognosis with supportive care.

In the major multicenter study of 402 isolated exposures, no deaths occurred, no seizures were observed, and life-threatening dysrhythmias were absent even at reported doses up to 1000 mg.

The later Texas poison-center analysis similarly found no deaths, ventricular dysrhythmias, or wide-QRS cases among 209 isolated acute overdoses.

Fatal cyclobenzaprine overdoses have nevertheless been reported, including cases with substantial postmortem cyclobenzaprine concentrations.

Thus the correct interpretation is:

Severe cardiotoxicity is rare—not impossible.

Pregnancy

The old FDA Pregnancy Category B terminology is obsolete.

Current extended-release labeling states that available human case-report data have not identified an increased risk of major birth defects, miscarriage, or adverse maternal/fetal outcomes, although the human evidence remains limited. Animal studies have shown reduced pup weight and survival at sufficiently high maternal exposures.

In acute overdose, maternal stabilization takes priority. Hypoxia, hypotension, seizures, and hyperthermia pose greater immediate fetal risks than most necessary resuscitative treatments.

Breastfeeding

Modern lactation data are more reassuring than the older statement that milk transfer was unknown.

The 2026 LactMed review reports that cyclobenzaprine concentrations in breast milk appear to be very low, with an estimated relative infant dose of approximately 0.5% in two studied mothers. Breastfeeding generally does not need to be stopped solely because therapeutic cyclobenzaprine is required.

The infant should nevertheless be monitored for excessive drowsiness, feeding problems, adequate weight gain, and respiratory depression, especially in neonates, preterm infants, or when the mother also receives opioids or other sedatives.

These therapeutic data should not automatically be extrapolated to a mother with a major acute overdose.

Older Adults

Cyclobenzaprine deserves particular caution in older adults because of sedation, antimuscarinic effects, confusion, urinary retention, and fall risk.

Current pharmacokinetic data show substantially increased drug exposure in elderly individuals.

A relatively modest overdose may therefore cause disproportionate delirium or sedation in an older patient.

Hepatic Impairment

Because cyclobenzaprine is extensively hepatically metabolized, plasma concentrations rise in hepatic dysfunction. Immediate-release labeling recommends cautious low-dose use in mild impairment and states that use in moderate-to-severe hepatic impairment is not recommended because adequate data are lacking.

This can prolong toxicity after overdose.

Important Pitfalls

A major pitfall is assuming that cyclobenzaprine is simply “amitriptyline without the antidepressant indication.” Its structure is similar, but poison-center data show that life-threatening sodium-channel cardiotoxicity is substantially less common in isolated cyclobenzaprine overdose.

The opposite error is equally dangerous: because cardiotoxicity is uncommon, clinicians should not ignore the ECG. New QRS widening or ventricular dysrhythmia requires immediate sodium bicarbonate treatment.

Another pitfall is treating simple sinus tachycardia with antiarrhythmics. Most tachycardia reflects antimuscarinic activity and does not need rhythm-specific therapy.

Do not use physostigmine reflexively simply because the patient is delirious and dry. Cyclobenzaprine has potential sodium-channel effects, and physostigmine is best reserved for carefully selected patients with a reassuring ECG after toxicology consultation.

The package insert’s routine recommendation for gastric lavage is outdated. Modern AACT/EAPCCT guidance states that lavage should not be performed routinely, if at all.

Another important modern pitfall is missing serotonin syndrome. Agitation, hyperthermia, diaphoresis, clonus, and hyperreflexia in a patient taking cyclobenzaprine with an SSRI, SNRI, tramadol, MAOI, or another serotonergic drug should not simply be labeled anticholinergic delirium.

Profound respiratory depression should trigger a search for opioids, ethanol, benzodiazepines, or other sedative coingestants rather than being automatically attributed to cyclobenzaprine.

Finally, do not use a serum cyclobenzaprine concentration to guide treatment. Current labeling specifically advises that plasma drug levels should not determine overdose management.

High-Yield Toxicology Pearls

Cyclobenzaprine overdose most commonly causes drowsiness + sinus tachycardia + antimuscarinic findings.

Its structure resembles a TCA, but large poison-center studies show that isolated cyclobenzaprine overdose much less commonly produces seizures, wide-QRS dysrhythmia, or fatal cardiotoxicity than amitriptyline overdose.

Current immediate-release dosing usually starts at 5 mg three times daily, with escalation to 7.5–10 mg three times daily if needed. Extended-release formulations contain 15 or 30 mg once daily. Therapy is generally limited to 2–3 weeks.

The main toxidrome is:

Sedation + tachycardia + dry mouth/skin + mydriasis + urinary retention ± antimuscarinic delirium

Always obtain an ECG after a significant overdose.

If there is QRS widening, ventricular dysrhythmia, or conduction-related hypotension, treat with:

Sodium bicarbonate 1–2 mEq/kg IV

and repeat according to ECG and hemodynamic response.

Sinus tachycardia alone does not require sodium bicarbonate.

Seizures are rare but should be treated with benzodiazepines. Phenytoin is not preferred for toxin-induced seizures.

Routine gastric lavage is obsolete despite language that persists in some current package inserts. Activated charcoal is selective rather than routine, with greatest potential benefit after a recent substantial ingestion when the airway is safe.

There is no specific antidote.

Physostigmine can reverse severe pure antimuscarinic delirium, but in cyclobenzaprine poisoning it should be highly selective, with a reassuring ECG and toxicology consultation; avoid it when QRS prolongation or another sodium-channel blocker is suspected.

Cyclobenzaprine can contribute to serotonin syndrome, especially with SSRIs, SNRIs, TCAs, tramadol, or MAO inhibitors. MAOI use is contraindicated during cyclobenzaprine treatment and for 14 days after MAOI discontinuation.

Hemodialysis does not meaningfully enhance elimination.

Most toxicity becomes evident within several hours after an immediate-release ingestion; a classic poison-center series found all eventually symptomatic patients with known timing had developed symptoms within 4 hours. Extended-release preparations and large or mixed ingestions require longer observation.

The most important clinical distinction is:

Cyclobenzaprine overdose usually behaves like an antimuscarinic sedative—but if the QRS widens, treat the patient like sodium-channel-blocker poisoning.

Toxicology – Cyanide

Core Concept

Cyanide is a rapidly acting cellular asphyxiant that prevents tissues from using oxygen despite adequate oxygen delivery. Severe poisoning can progress within minutes from headache, confusion, and dyspnea to seizures, profound lactic acidosis, cardiovascular collapse, coma, and death.

The key mechanism is:

Cyanide exposure → inhibition of mitochondrial cytochrome c oxidase → oxidative phosphorylation stops → cellular ATP failure → anaerobic metabolism → massive lactate production → cardiovascular/CNS collapse

The most important modern treatment principle is:

Suspected severe cyanide poisoning → give 100% oxygen + aggressive supportive care + hydroxocobalamin early; do not wait for a cyanide level.

Hydroxocobalamin is FDA-approved for known or suspected cyanide poisoning and can be administered immediately when clinical suspicion is high.

Forms and Sources

Important cyanide exposures include hydrogen cyanide (HCN) gas, sodium cyanide, potassium cyanide, calcium cyanide, cyanogen compounds, cyanogenic plants, nitriles, sodium nitroprusside, and combustion products from structural fires.

Hydrogen cyanide is a volatile liquid/gas that can be rapidly lethal by inhalation. Cyanide salts can generate HCN when exposed to acid, including gastric acid after ingestion.

Industrial exposures occur in mining and metal extraction, electroplating, metallurgy, jewelry manufacture, plastics and synthetic-fiber production, chemical manufacturing, fumigation, and laboratory processes.

Smoke Inhalation

Modern toxicology places particular emphasis on enclosed-space structural fires.

Combustion of nitrogen-containing synthetic materials can generate hydrogen cyanide. A fire victim may therefore have simultaneous:

thermal injury + airway injury + carbon monoxide poisoning + cyanide poisoning

Cyanide should be particularly suspected after an enclosed-space fire when the patient has altered consciousness, seizures, cardiovascular instability, severe metabolic/lactic acidosis, or cardiac arrest.

Not every smoke-inhalation victim has clinically significant cyanide poisoning, however. Empiric hydroxocobalamin use in smoke inhalation remains an area of imperfect evidence; recent systematic reviews emphasize that outcome data are largely observational and that indiscriminate administration to every smoke-exposed patient is not supported.

Cyanogenic Plants and Foods

Cyanogenic glycosides can release cyanide after enzymatic hydrolysis. Important sources include bitter cassava, apricot kernels, bitter almonds, peach and cherry pits, and certain other seeds and plants.

Proper processing of cassava substantially reduces cyanogenic compounds. Poisoning is more likely after consumption of inadequately processed bitter cassava or concentrated cyanogenic products than after ordinary consumption of fruit flesh.

Amygdalin/laetrile is particularly important because it can release cyanide and has caused serious poisoning.

Nitroprusside

Sodium nitroprusside metabolism releases cyanide. Toxicity becomes more likely with high-dose or prolonged infusions, particularly when detoxification pathways are overwhelmed.

Cyanide generated from nitroprusside is normally converted to thiocyanate, which is predominantly eliminated by the kidneys. Prolonged exposure may therefore also produce thiocyanate accumulation, especially in renal dysfunction.

Toxic Dose

There is no single clinically reliable toxic dose because toxicity depends on the cyanide compound, route, concentration, duration, gastrointestinal conditions, and speed of treatment.

Hydrogen cyanide inhalation can cause extremely rapid poisoning because pulmonary absorption is nearly immediate. The historical statement that approximately 90 ppm for 30 minutes may be lethal should not be treated as a clinical threshold.

NIOSH lists hydrogen cyanide as having a REL of 4.7 ppm (5 mg/m³) as a short-term exposure limit with skin notation; the current OSHA PEL listed by NIOSH is 10 ppm (11 mg/m³) as an 8-hour TWA with skin notation. NIOSH historically designated 50 ppm as immediately dangerous to life or health.

Reported lethal oral doses of cyanide salts vary widely, and a quoted value such as “200 mg” should therefore not be used as a reliable bedside cutoff.

Pathophysiology

Cyanide has a high affinity for the ferric iron within cytochrome c oxidase (Complex IV) of the mitochondrial electron transport chain.

Normally:

O₂ → final electron acceptor → oxidative phosphorylation → ATP

With cyanide:

Cytochrome oxidase inhibited → O₂ cannot be effectively utilized → oxidative phosphorylation stops → ATP depletion → anaerobic glycolysis → lactate accumulation

This produces histotoxic hypoxia: oxygen may reach the tissues, but cells cannot use it normally.

The brain and heart are particularly vulnerable because of their high metabolic requirements.

Venous Hyperoxia

Because tissues cannot adequately extract oxygen, venous blood may remain unusually oxygenated. This explains the classic description of unusually bright venous blood or reduced arterial–venous oxygen difference.

However, this finding is neither sufficiently sensitive nor specific to diagnose cyanide poisoning and should not delay treatment.

Clinical Features

Cyanide poisoning is primarily a neurologic, cardiovascular, and metabolic catastrophe.

Early manifestations may include headache, dizziness, anxiety, agitation, confusion, nausea, vomiting, dyspnea, tachypnea, tachycardia, and hypertension.

As toxicity progresses:

agitation/confusion → seizures → coma → hypotension → bradycardia → apnea → cardiovascular collapse

Large inhalational exposures can produce this sequence within minutes. CDC describes rapid development of respiratory abnormalities, altered mental status, seizures, loss of consciousness, blood-pressure abnormalities, coma, and death after substantial exposure.

Cardiovascular Toxicity

Early sympathetic activation can produce tachycardia and hypertension.

Severe cellular hypoxia then produces myocardial dysfunction, dysrhythmias, hypotension, bradycardia, and ultimately cardiovascular collapse.

Profound hypotension after a credible cyanide exposure is therefore a major indication for immediate antidotal therapy.

Neurologic Toxicity

Early neurologic manifestations include headache, dizziness, restlessness, anxiety, and confusion.

Severe poisoning causes altered consciousness, generalized seizures, coma, and respiratory arrest.

Patients who survive profound poisoning may develop hypoxic-ischemic brain injury or delayed neurologic syndromes including movement disorders and parkinsonian features.

Respiratory Findings

Tachypnea is common initially because of metabolic acidosis and CNS stimulation.

Severe poisoning may progress to central respiratory depression, apnea, and respiratory arrest.

Smoke inhalation may simultaneously produce upper-airway thermal injury, bronchospasm, chemical pneumonitis, and pulmonary edema, so respiratory failure in a fire victim is frequently multifactorial.

Gastrointestinal Findings

Ingested cyanide salts commonly produce nausea, vomiting, abdominal pain, and rapidly developing systemic toxicity.

Onset may be slower than with inhaled hydrogen cyanide, but substantial salt ingestion remains a medical emergency.

Certain cyanogenic glycosides and nitriles can produce more delayed toxicity because cyanide must first be liberated metabolically.

Skin Exposure

Hydrogen cyanide and some cyanide compounds can be absorbed through skin, particularly when liquid contamination is present.

Contaminated clothing should therefore be removed promptly and exposed skin irrigated thoroughly.

Some cyanide salts can additionally cause local irritation or chemical injury.

“Bitter Almond” Odor

The classic bitter-almond odor associated with cyanide is unreliable.

Many people cannot genetically perceive the odor, concentrations may be insufficient to smell, and deliberately smelling a suspected cyanide source is dangerous.

Therefore:

Absence of a bitter-almond odor does not exclude cyanide poisoning.

Cyanosis

Cyanosis is not a reliable early finding. Because the primary problem is failure of cellular oxygen utilization rather than failure of oxygen delivery, severe poisoning may occur without prominent cyanosis.

Diagnosis

Cyanide poisoning is primarily a clinical diagnosis.

The combination of:

credible exposure + neurologic deterioration + cardiovascular instability + severe unexplained lactic acidosis

should trigger immediate consideration of cyanide.

Treatment should never be delayed while waiting for confirmatory testing when severe poisoning is clinically suspected. Both hydroxocobalamin and nitrite/thiosulfate labeling emphasize prompt antidotal treatment when suspicion is high.

Serum Lactate

Lactate is one of the most useful rapidly available laboratory clues.

Cyanide-induced inhibition of oxidative phosphorylation causes dramatic anaerobic lactate production. A markedly elevated lactate following an appropriate exposure strongly supports the diagnosis.

In smoke-inhalation literature, an arterial lactate >8 mmol/L increases concern for cyanide exposure, while approximately ≥10 mmol/L has historically been used as a stronger indicator of significant cyanide toxicity.

These are decision-support thresholds, not absolute diagnostic cutoffs. Lactate can also rise from burns, seizures, shock, carbon monoxide poisoning, catecholamines, trauma, or cardiac arrest.

Thus:

High lactate + compatible exposure + neurologic/cardiovascular collapse is much more important than lactate alone.

Acid–Base Findings

Severe poisoning typically causes a high-anion-gap metabolic acidosis with elevated lactate.

Obtain blood gas, electrolytes, bicarbonate, lactate, glucose, and renal function in significantly symptomatic patients.

Profound acidosis supports severe cellular poisoning but is not specific for cyanide.

Cyanide Concentrations

Whole-blood cyanide concentrations can confirm exposure but are usually not useful for acute treatment decisions because results are often unavailable quickly enough.

Cyanide is also unstable in biologic specimens, making proper collection and handling important. Published reviews note that cyanide measurements may require hours while critically poisoned patients can die within minutes.

Therefore:

Never wait for a cyanide concentration before treating a critically ill patient.

The old tables correlating individual cyanide concentrations with tachycardia, obtundation, coma, or death are too rigid for modern bedside use.

Additional Investigations

Obtain continuous ECG monitoring in significant poisoning. Troponin may be useful when myocardial injury is suspected.

In smoke-inhalation patients, measure carboxyhemoglobin by co-oximetry because concomitant carbon monoxide poisoning is common.

Other testing should be guided by the circumstances and may include CBC, renal and liver function, CK, toxicology testing, chest imaging, and evaluation for trauma or burns.

An intentional ingestion should prompt testing for relevant occult coingestants such as acetaminophen according to standard overdose practice.

Differential Diagnosis

The most important toxicologic mimics include carbon monoxide, hydrogen sulfide, methemoglobinemia, sodium azide, toxic alcohols, salicylates, iron, isoniazid, and other cellular or chemical asphyxiants.

Nontoxicologic causes include sepsis, cardiogenic shock, status epilepticus, severe hypoxemia, diabetic or alcoholic ketoacidosis, mesenteric ischemia, and other causes of profound lactic acidosis.

In an enclosed-space fire, cyanide and carbon monoxide should not be considered mutually exclusive:

CO poisoning + cyanide poisoning can coexist.

Immediate Treatment

Management begins simultaneously with diagnosis.

Remove the patient from exposure while protecting rescuers. Give 100% oxygen immediately, establish airway and ventilatory support as required, obtain IV/IO access, treat seizures, support circulation, correct life-threatening metabolic disturbances, and administer an antidote promptly when severe cyanide poisoning is suspected.

FDA labeling specifically emphasizes that antidote administration must occur together with airway, ventilation, circulatory support, oxygen, and seizure management.

Oxygen

Give 100% oxygen, even if pulse oximetry appears normal.

Cyanide prevents normal oxygen utilization rather than necessarily lowering arterial oxygen content. Supplemental oxygen therefore does not correct the fundamental biochemical lesion, but it maximizes available oxygen and is particularly important because pulmonary injury and carbon monoxide poisoning may coexist.

Pulse oximetry cannot rule out either cyanide or carbon monoxide poisoning.

Airway and Ventilation

Early intubation is appropriate for progressive coma, recurrent seizures, inadequate ventilation, severe hypoxemia, respiratory failure, or anticipated airway edema after smoke inhalation.

Mechanical ventilation should use a high inspired oxygen concentration initially.

Seizures

Treat seizures promptly with benzodiazepines.

Persistent seizures can dramatically increase lactate production and oxygen demand and should be treated aggressively using standard status-epilepticus escalation if necessary.

Hypotension and Shock

Give appropriate isotonic crystalloid while avoiding unnecessary volume overload.

Persistent shock should be treated with a titratable vasopressor. Norepinephrine is generally the preferred first-line vasopressor for undifferentiated distributive or vasoplegic shock rather than the historical dopamine-first strategy.

Severe cyanide-induced shock may improve rapidly after effective antidotal therapy.

The Trendelenburg position is obsolete as a treatment for shock.

Antidote – Hydroxocobalamin

Hydroxocobalamin is the preferred modern antidote for most suspected severe cyanide poisoning.

Hydroxocobalamin binds cyanide to form cyanocobalamin, which is substantially less toxic and eliminated in the urine.

Its major advantage is that it does not intentionally induce methemoglobinemia, making it especially attractive when carbon monoxide poisoning or smoke-induced hypoxemia may coexist.

CYANOKIT is FDA-approved for known or suspected cyanide poisoning.

Hydroxocobalamin Dose

For adults:

Hydroxocobalamin 5 g IV over 15 minutes

If severe toxicity persists or recurs, a second 5-g IV dose may be given, for a maximum total dose of 10 g according to current U.S. labeling. The second dose may be infused over approximately 15 minutes to 2 hours depending on clinical severity.

Pediatric hydroxocobalamin dosing is generally 70 mg/kg IV, maximum 5 g for the initial dose, with repeat dosing considered in severe poisoning according to toxicology protocols and specialist guidance.

Antidotal treatment should not be delayed for laboratory confirmation.

Hydroxocobalamin Adverse Effects

Hydroxocobalamin commonly causes dramatic but usually benign red discoloration of the skin and urine (chromaturia).

Other effects include transient hypertension, nausea, headache, rash, infusion reactions, and occasional hypersensitivity.

Current labeling also warns of acute kidney injury and urinary calcium oxalate crystals, and recommends renal-function monitoring after treatment.

Recent observational literature has raised concern about an association between hydroxocobalamin and AKI in smoke-inhalation patients, although causality is difficult to establish because these patients are often critically ill.

Laboratory Interference After Hydroxocobalamin

The intense red coloration of hydroxocobalamin can interfere with colorimetric laboratory assays and some bedside or dialysis equipment.

The laboratory should therefore be informed immediately that hydroxocobalamin has been administered.

This interference can affect interpretation of several chemistry, hematology, and co-oximetry measurements depending on the analyzer.

Hemodialysis After Hydroxocobalamin

The red pigment can trigger false blood-leak alarms on some hemodialysis machines, potentially complicating renal replacement therapy.

This is clinically important in severely ill fire victims who develop AKI.

Sodium Nitrite and Sodium Thiosulfate

The traditional cyanide antidote kit used:

Sodium nitrite → methemoglobin formation → cyanide binding

followed by:

Sodium thiosulfate → sulfur donor → conversion of cyanide to thiocyanate

The combination remains FDA-approved as NITHIODOTE for serious or life-threatening acute cyanide poisoning.

However, it is no longer the preferred empiric strategy for many smoke-inhalation patients when hydroxocobalamin is available.

Why Sodium Nitrite Can Be Dangerous

Sodium nitrite deliberately oxidizes hemoglobin to methemoglobin, which binds cyanide.

The problem is that methemoglobin cannot carry oxygen normally.

In an enclosed-space fire victim who may already have:

carbon monoxide → reduced functional hemoglobin

plus

smoke/airway injury → impaired oxygenation

creating additional methemoglobinemia can further compromise oxygen delivery.

Sodium nitrite can also cause hypotension, which is particularly undesirable in cyanide-induced cardiovascular collapse. Current NITHIODOTE labeling specifically warns about hypotension and methemoglobin formation.

Therefore:

Avoid routine nitrite administration in smoke-inhalation patients when significant CO poisoning or impaired oxygen delivery is possible and hydroxocobalamin is available.

NITHIODOTE Dosing

If the nitrite/thiosulfate regimen is selected for serious confirmed or strongly suspected cyanide poisoning, current U.S. labeling recommends in adults:

Sodium nitrite 300 mg IV — supplied as 10 mL — administered slowly, followed immediately by sodium thiosulfate 12.5 g IV — supplied as 50 mL.

For children, sodium nitrite is 6 mg/kg IV, maximum 300 mg, followed by sodium thiosulfate 250 mg/kg IV, maximum 12.5 g. If toxicity recurs, one-half of the original doses may be repeated.

Blood pressure must be monitored during nitrite administration.

Hydroxocobalamin Plus Thiosulfate

Sodium thiosulfate has historically been used as an adjunct because it enhances conversion of cyanide to thiocyanate.

However, modern management usually prioritizes hydroxocobalamin when rapid empiric therapy is needed.

If hydroxocobalamin and nitrite/thiosulfate products are used in the same patient, compatibility matters: current product labeling states that NITHIODOTE components are chemically incompatible with hydroxocobalamin and should not be administered through the same IV line.

Decontamination – Inhalation

Rescuers must not enter a contaminated atmosphere without appropriate respiratory protection.

Remove the patient to fresh air and administer 100% oxygen.

A patient exposed only to cyanide gas who has no liquid or particulate contamination generally does not require extensive skin decontamination once removed from the source.

Decontamination – Dermal Exposure

Remove contaminated clothing and jewelry promptly.

Wash contaminated skin thoroughly with water and soap as appropriate while preventing secondary contamination of staff.

Liquid hydrogen cyanide and soluble cyanide compounds can be absorbed through skin, making rapid removal important.

Decontamination – Ingestion

Do not induce vomiting.

Ipecac is obsolete.

Routine gastric lavage is also not recommended because of aspiration risk, rapid cyanide absorption, and potential danger to staff from released hydrogen cyanide.

Activated charcoal may be considered after a very recent significant oral exposure when the airway is intact or protected, but it must never delay airway stabilization or antidote administration.

Because severe cyanide poisoning can progress extremely rapidly, antidote and resuscitation take priority over gastrointestinal decontamination.

Sodium Bicarbonate

Metabolic acidosis usually improves when cyanide toxicity, shock, seizures, and hypoxia are corrected.

Sodium bicarbonate is not an antidote to cyanide.

It may be used selectively for severe life-threatening acidemia according to ordinary critical-care principles, but routine administration based solely on cyanide exposure is not indicated.

Hyperbaric Oxygen

Hyperbaric oxygen is not a standard antidotal treatment for isolated cyanide poisoning.

The historical suggestion that HBO prevents delayed neurologic injury from cyanide is not supported sufficiently to justify routine use.

In smoke-inhalation patients, hyperbaric oxygen may be considered independently for significant carbon monoxide poisoning according to CO-specific indications, but transport to an HBO facility must never delay hydroxocobalamin, airway management, seizure control, or hemodynamic resuscitation.

Extracorporeal Elimination

Hemodialysis is not routinely used to remove cyanide itself because poisoning evolves too rapidly and effective antidotes are available.

Renal replacement therapy may nevertheless be required for conventional indications such as severe AKI, refractory electrolyte disturbance, or acid-base abnormalities.

Thiocyanate generated during cyanide detoxification is renally eliminated and can accumulate in renal failure, particularly during prolonged sodium nitroprusside exposure.

Smoke-Inhalation Decision Making

In an enclosed-space fire victim, empiric hydroxocobalamin is most compelling when there is a combination such as:

altered consciousness or coma + severe lactic acidosis + hypotension/cardiovascular collapse ± seizures/cardiac arrest

Soot around the mouth or nose, carbonaceous sputum, burns, and enclosed-space exposure strengthen the history but do not by themselves prove cyanide poisoning.

An unexplained lactate around 8–10 mmol/L or higher substantially increases suspicion in the correct clinical context.

Because recent evidence remains observational and heterogeneous, hydroxocobalamin should not be viewed as mandatory for every patient who merely inhaled smoke.

Cardiac Arrest

Cyanide should be considered in otherwise unexplained cardiovascular collapse or cardiac arrest immediately following a credible high-concentration exposure or enclosed-space fire.

Standard high-quality resuscitation should continue while 100% oxygen and hydroxocobalamin are administered when severe cyanide poisoning is suspected.

Successful resuscitation is possible even after profound poisoning when antidotal therapy and cardiovascular support are delivered rapidly.

Pregnancy

Pregnancy should not delay life-saving antidotal treatment.

Severe maternal cyanide poisoning threatens both mother and fetus through profound cellular hypoxia. Maternal stabilization and rapid antidotal treatment therefore take priority.

Specialist toxicology and obstetric involvement is appropriate after stabilization.

Monitoring

Severely poisoned patients require continuous ECG, blood pressure, oxygenation, respiratory, temperature, and neurologic monitoring.

Serial lactate, blood gas/pH, electrolytes, glucose, renal function, and markers of end-organ injury help determine response to treatment.

After hydroxocobalamin, monitor renal function and recognize that several laboratory measurements may be analytically distorted by the drug’s intense red pigmentation. Current labeling recommends monitoring renal function for 7 days following treatment.

Admission and Disposition

Any patient with significant neurologic symptoms, severe lactic acidosis, cardiovascular instability, respiratory compromise, substantial intentional ingestion, or requirement for antidotal treatment should be admitted, usually to an ICU.

Minor exposures with no symptoms and reassuring serial assessment may eventually be discharged after an exposure-specific observation period. A rigid historical 8-hour observation rule should not be applied to every cyanide exposure.

Delayed toxicity is more relevant after cyanogenic glycosides, certain nitriles, or potentially ongoing gastrointestinal absorption than after a brief low-level HCN inhalation.

Intentional exposure requires appropriate psychiatric assessment after medical stabilization.

Prognosis

Outcome is strongly dependent on dose, route, duration of exposure, and speed of resuscitation and antidotal therapy.

Massive HCN inhalation may cause death within minutes.

Patients who regain cardiovascular and neurologic function rapidly may recover completely. Patients who experience prolonged coma, seizures, severe hypotension, or cardiac arrest are at risk for hypoxic-ischemic brain injury.

Delayed neurologic sequelae have been described after severe poisoning, including cognitive impairment, movement disorders, and parkinsonism.

Important Pitfalls

The first major pitfall is waiting for a cyanide concentration. Cyanide poisoning is treated clinically; laboratory confirmation is generally too slow to guide emergency antidotal therapy.

The second is assuming normal pulse oximetry excludes poisoning. Cyanide is a cellular oxygen-utilization poison, so SpO₂ may appear reassuring despite profound mitochondrial hypoxia.

The third is relying on the smell of bitter almonds. Odor perception is unreliable and should never determine diagnosis.

The fourth is overlooking cyanide in an enclosed-space fire victim with coma, hypotension, seizures, or marked lactic acidosis.

The fifth is treating every smoke-inhalation patient automatically with hydroxocobalamin. Empiric treatment is most defensible when clinical findings suggest significant cyanide toxicity; recent evidence for indiscriminate use remains uncertain.

The sixth is using sodium nitrite indiscriminately in a smoke-inhalation victim. Nitrite-induced methemoglobinemia can further compromise oxygen delivery when carbon monoxide poisoning and pulmonary injury already coexist.

The seventh is allowing decontamination, imaging, laboratory testing, or hyperbaric transfer to delay antidotal therapy in a critically ill patient.

Finally, after hydroxocobalamin, remember the striking red skin and urine discoloration, laboratory interference, possible AKI, and interference with some hemodialysis blood-leak detectors.

High-Yield Toxicology Pearls

Cyanide = histotoxic hypoxia.

The core mechanism is:

Cyanide → cytochrome c oxidase inhibition → oxidative phosphorylation failure → ATP depletion → anaerobic metabolism → severe lactic acidosis

The classic severe syndrome is:

Rapid altered mental status/seizures + profound lactic acidosis + hypotension/cardiovascular collapse

Think particularly about cyanide after an enclosed-space structural fire, industrial exposure, cyanide-salt ingestion, cyanogenic plant ingestion, or problematic nitroprusside exposure.

A markedly elevated lactate—particularly around 8–10 mmol/L or greater in a compatible smoke-inhalation presentation—strongly increases suspicion but is not diagnostic by itself.

Blood cyanide levels can confirm exposure but are usually too slow to guide emergency treatment.

Give 100% oxygen even when SpO₂ is normal.

For severe known or suspected poisoning:

Hydroxocobalamin 5 g IV over 15 minutes

A second 5 g may be administered if severe toxicity persists or recurs, for an adult total of 10 g.

Hydroxocobalamin is particularly advantageous in smoke inhalation because it does not induce methemoglobinemia.

Expect red skin and urine, laboratory interference, transient hypertension, and possible renal injury after hydroxocobalamin.

The traditional sodium nitrite + sodium thiosulfate antidote regimen remains FDA-approved, but nitrite produces methemoglobinemia and hypotension and is therefore problematic when carbon monoxide poisoning or impaired oxygen delivery coexists.

Do not induce vomiting. Routine gastric lavage is obsolete. Activated charcoal has only a selective role after very recent oral exposure and must never delay resuscitation or antidote.

Hyperbaric oxygen is not routine treatment for isolated cyanide poisoning; in a fire victim it may be considered separately for significant concomitant carbon monoxide poisoning.

Most importantly:

If severe cyanide poisoning is clinically likely, treat first—the patient can die long before the cyanide level returns.

Toxicology – Cone Snail Envenomation

Core Concept

Cone snails are venomous marine gastropods whose sting can produce a rapidly progressive neuroparalytic syndrome. Most human stings cause only local symptoms, but envenomation by large fish-hunting species—particularly Conus geographus, the geography cone—can progress from localized numbness to cranial neuropathies, generalized flaccid paralysis, respiratory failure, cardiac arrest, and death.

A useful toxicologic sequence is:

Cone-snail sting → conopeptide neurotoxins → ion-channel/receptor blockade → neuromuscular paralysis → respiratory failure

The most important modern treatment is not hot-water immersion. It is:

Pressure immobilization + complete physical rest + early respiratory monitoring/support

There is no antivenom. Survival from severe envenomation depends primarily on maintaining ventilation until the venom effects wear off. Current Australian emergency guidance treats cone-shell envenomation as potentially fatal and specifically recommends pressure immobilization, splinting, close neurologic and respiratory observation, and assisted ventilation when necessary.

Species and Distribution

The old estimate of 300–500 species is outdated. More than 900 cone-snail species are now recognized, occurring predominantly in tropical and subtropical marine environments. They are especially diverse in the Indo-Pacific and commonly inhabit coral reefs, rocky areas, sand, and shallow coastal habitats.

Cone snails are predatory. Different species specialize in eating marine worms, other mollusks, or fish. The fish-hunting species are generally the most dangerous to humans because their venoms evolved to rapidly immobilize vertebrate prey.

Conus geographus – The Most Dangerous Species

The geography cone, Conus geographus, is overwhelmingly the species of greatest human toxicologic importance. A comprehensive review of documented cases through 2017 identified 141 reported human envenomations with 36 deaths. Approximately 57% of all known stings were attributed to C. geographus, and the authors concluded that most or possibly all reliably documented human fatalities were caused by this species.

The historical statement that Conus tulipa has “the most toxic venom” should not be used clinically. Venom potency varies substantially according to species, toxin composition, prey type, defensive versus predatory venom, and the amount injected. In real-world human envenomation, C. geographus has by far the strongest association with fatality.

How the Sting Occurs

Cone snails possess specialized hollow radular teeth that function like miniature disposable harpoons. A tooth is connected through the proboscis to the venom apparatus, allowing the snail to inject a complex venom mixture into prey—or into a person’s hand when the animal is handled.

Human stings most often occur when someone picks up a live cone shell while:

• Collecting shells
• Walking or diving on reefs
• Handling snails in aquaria
• Fishing or beachcombing

The shell itself may appear empty while the living snail remains retracted deeply within it. A person should therefore never assume that an attractive cone shell is safe to handle.

Predatory and Defensive Venom

Modern research has shown that cone snails can deploy different venom mixtures for prey capture and defense. Defensive venom, which is particularly relevant to human stings, may contain paralytic toxins different from those preferentially released while hunting prey.

This helps explain why simple descriptions of “the conotoxin” are misleading. Cone-snail venom is not a single toxin but an extremely complex mixture of biologically active peptides, with individual species producing hundreds to potentially thousands of different components.

Conotoxins

Cone-snail venom contains numerous conopeptides, many of which act with extraordinary selectivity on ion channels and neurotransmitter receptors.

Important toxin families include α-conotoxins, which inhibit nicotinic acetylcholine receptors; ω-conotoxins, which inhibit voltage-gated calcium channels; μ-conotoxins, which block voltage-gated sodium channels in skeletal muscle; and κ-conotoxins, which affect potassium channels.

The combined effect is disruption of neural and neuromuscular transmission, resulting in sensory abnormalities, cranial nerve dysfunction, weakness, and potentially complete flaccid paralysis.

The older description of one specific “virgotoxin” as a major clinically important cardiotoxic protein is not central to contemporary understanding of human cone-snail envenomation. Modern toxicology emphasizes the combined neurophysiologic actions of numerous conopeptides, rather than attributing the syndrome to a single cardiac toxin.

α-Conotoxins

α-Conotoxins act principally on nicotinic acetylcholine receptors at neuromuscular junctions and neuronal synapses. By interfering with acetylcholine-mediated transmission, they can contribute to progressive weakness and paralysis.

The clinical effect resembles a pharmacologic neuromuscular block:

Motor nerve signal → blocked nicotinic transmission → muscle weakness/paralysis

Respiratory muscles can be affected, making ventilatory failure the principal life-threatening complication.

ω-Conotoxins

ω-Conotoxins inhibit selected voltage-gated calcium channels, reducing neurotransmitter release from nerve terminals.

One synthetic conopeptide derived from Conus magus, ziconotide, is used medically as an intrathecal analgesic. This illustrates the highly specific pharmacologic actions of cone-snail toxins, although ziconotide therapy is separate from management of natural envenomation.

μ-Conotoxins

μ-Conotoxins inhibit voltage-gated sodium channels in skeletal muscle and thereby impair muscle action-potential propagation. This contributes to rapid paralysis in vertebrate prey and potentially to generalized weakness after severe human envenomation.

Toxic Dose

There is no measurable human “toxic dose” after a natural sting. Severity depends on the species, size of the snail, amount of venom injected, sting location, victim size, and possibly whether the snail delivered a predatory or defensive venom mixture.

A single sting from a large C. geographus can be fatal. Fatal cases have historically occurred after one sting, emphasizing that the absence of multiple punctures does not imply a low-risk exposure.

Clinical Onset

Symptoms usually begin rapidly after clinically important envenomation. Local pain or numbness may be immediate, while systemic neurologic symptoms can evolve over minutes to several hours.

Severe envenomation may progress to respiratory or cardiac arrest within approximately 40 minutes to several hours. Current Queensland emergency guidance describes severe paralysis and arrest within this early period.

Therefore:

Do not wait for respiratory distress before treating a potentially serious cone-snail sting as dangerous.

Local Effects

The sting may initially cause sharp pain, burning, tingling, numbness, swelling, or localized weakness. Surprisingly, some stings may be only mildly painful, particularly relative to the severity of later paralysis.

Localized numbness can spread proximally from the sting site. Older reports also describe local pallor, discoloration, or cyanosis, but ischemic skin injury is not the defining toxic effect.

A puncture wound may be extremely small and difficult to identify.

Early Neurologic Symptoms

The hallmark of systemic envenomation is progressive neurologic dysfunction. Early manifestations can include perioral tingling, numbness of the lips and tongue, spreading paresthesias, weakness, dizziness, blurred or double vision, ptosis, speech difficulty, and dysphagia.

Perioral symptoms are especially important because they may herald evolving cranial and bulbar dysfunction.

Progressive Paralysis

Severe envenomation can progress to muscle incoordination, generalized weakness, flaccid paralysis, loss of effective swallowing, and respiratory-muscle paralysis.

An extremely important clinical feature is that the patient may remain:

Conscious and aware despite profound paralysis

Current Queensland guidance specifically warns clinicians to reassure patients because a severely paralyzed victim may remain fully aware.

A motionless patient should therefore not automatically be assumed unconscious.

Respiratory Failure

The older statement that respiratory paralysis had not been reported in humans is incorrect.

Respiratory paralysis is the major life-threatening manifestation of severe human cone-snail envenomation.

Current Australian clinical guidance explicitly recognizes progressive swallowing and breathing difficulty followed by respiratory paralysis, and reviews of human envenomation document paralysis progressing to respiratory or cardiac arrest.

Because the respiratory muscles may progressively fail while consciousness is preserved, respiratory rate alone can be misleading. Serial assessment of:

• Work of breathing
• Tidal volume
• Speech
• Swallowing
• Oxygenation
• Ventilation
• Respiratory muscle strength

is essential.

Cardiovascular Effects

Cardiovascular abnormalities are less consistent than neurologic paralysis but may include tachycardia, bradycardia, hypotension, rhythm disturbance, or cardiovascular arrest in catastrophic envenomation.

Some observed tachycardia may reflect anxiety and stress rather than direct cardiotoxicity. The principal mechanism of death remains paralysis with respiratory failure, although severe hypoxia can ultimately produce cardiac arrest.

Diagnosis

Diagnosis is primarily clinical and rests on a compatible marine exposure together with rapidly developing local neurologic symptoms or paralysis.

A particularly suggestive history is:

Handling a cone-shaped marine shell → puncture/sting → local numbness → spreading paresthesias/cranial symptoms → weakness

Whenever possible, identification of the shell can help assess risk. However, treatment must not be delayed while attempting to identify the exact species.

Do not handle or bring a live snail into the treatment area.

Differential Diagnosis

The differential includes blue-ringed octopus envenomation, sea-snake envenomation, tetrodotoxin poisoning, paralytic shellfish poisoning, botulism, acute stroke, Guillain-Barré syndrome, myasthenic crisis, and other causes of rapidly evolving neuromuscular paralysis.

Blue-ringed octopus toxicity is particularly similar because it also produces rapid flaccid paralysis with potentially preserved consciousness and minimal local injury.

A history of handling a cone shell is therefore extremely valuable.

Laboratory Testing

There is no clinically available conotoxin blood test. Laboratory testing should be guided by severity rather than ordered routinely after every minor sting.

In symptomatic systemic envenomation, useful assessments may include:

• Glucose
• Electrolytes
• Renal function
• Blood gas if ventilation is impaired
• Lactate in severe illness

These tests assess physiologic consequences rather than quantify venom.

Respiratory Monitoring

Pulse oximetry should be used in symptomatic patients, but a normal oxygen saturation does not prove that ventilation is adequate, particularly if supplemental oxygen is being administered.

Capnography or blood-gas assessment can help identify evolving hypoventilation and hypercapnia.

Serial respiratory muscle assessment is particularly important when dysphagia, dysarthria, ptosis, or generalized weakness develops.

ECG and Cardiac Monitoring

Patients with systemic envenomation should receive continuous cardiac monitoring. An ECG is appropriate when there is significant weakness, hypoxia, hypotension, palpitations, or other systemic toxicity.

Cardiac monitoring should not distract from the primary danger, which is progressive neuromuscular respiratory failure.

Immediate First Aid

The historical chapter recommended treating the sting like a snakebite but also emphasized hot-water immersion. Modern first aid is clearer.

For a suspected cone-snail sting:

Keep the patient still, call emergency medical services, and apply pressure immobilization to the affected limb.

Pressure immobilization is recommended by current Australian national/state guidance for cone-shell stings because limiting lymphatic movement can slow systemic venom spread.

A broad pressure bandage should cover the sting area and the involved limb, and the limb should be immobilized with a splint. The patient should remain as motionless as possible.

Pressure Immobilization

The purpose of pressure immobilization is not to stop arterial flow. Instead it reduces lymphatic transport of venom.

The bandage should therefore be firm but not a tourniquet. The limb should be splinted, and walking or unnecessary movement should be avoided.

If an effective pressure-immobilization bandage has already been applied:

Do not repeatedly remove it for inspection during transport.

Current Queensland protocols specifically advise leaving it in place while the patient remains immobilized and is transferred for definitive care.

Hot-Water Immersion – Important Modern Correction

The older text states that the wound should be immersed in water around 105°F to “inactivate” the toxin.

This is not current first-line treatment for cone-snail envenomation.

Modern Australian first-aid recommendations use pressure immobilization, not hot-water immersion, for cone shells. Hot water is recommended for painful envenomations from animals such as stonefish and some other marine creatures, but cone-shell stings are treated differently because the major danger is systemic neurotoxin spread.

There is no good clinical evidence that hot water reliably denatures injected conotoxins in human tissue or prevents systemic paralysis.

Therefore:

Do not delay pressure immobilization, emergency transport, or respiratory support in order to perform hot-water immersion.

Do Not Use a Tourniquet

A tourniquet should not be applied. Complete arterial occlusion creates ischemic injury and is not the goal of venom first aid.

Likewise:

• Do not cut the wound
• Do not suck out venom
• Do not apply caustic chemicals
• Do not attempt to capture the live snail

Airway and Ventilation

The definitive lifesaving treatment for severe cone-snail envenomation is:

Effective ventilation until paralysis resolves.

If respiratory muscle weakness progresses, provide bag-mask ventilation immediately when needed and prepare for early endotracheal intubation.

Intubation should be strongly considered with:

• Progressive respiratory weakness
• Bulbar dysfunction
• Dysphagia
• Inability to handle secretions
• Declining tidal volume
• Hypercapnia
• Respiratory arrest

Current Queensland guidance emphasizes that bag-valve-mask ventilation can be lifesaving and that intubation may be required before transfer in patients developing respiratory failure.

Prolonged Ventilation

If the circulation is maintained, even profound neuroparalysis can be survivable because venom effects eventually wear off.

Current Queensland emergency protocols caution that severe paralytic marine envenomation may require prolonged mechanical ventilation, potentially for days, until neuromuscular function returns.

This makes early recognition and high-quality supportive care extraordinarily important.

Analgesia

Local pain should be treated according to severity. Many victims require only simple analgesia, while some may need stronger medication.

Opioids can be used when clinically necessary, but in a patient with evolving neuromuscular respiratory weakness they must be titrated carefully because additional respiratory depression can complicate assessment.

Pain control is secondary to airway and respiratory monitoring.

Wound Care

After the immediate envenomation risk has been managed, the puncture wound should be assessed for:

• Retained foreign material
• Local infection
• Tissue injury

Standard wound hygiene is appropriate.

Tetanus immunization should be updated according to routine wound-management guidelines.

Routine prophylactic antibiotics are not required for every uncomplicated cone-snail sting unless there is:

• Significant contamination
• Established infection
• Another specific indication

Antidote

There is no cone-snail antivenom or clinically available specific antidote.

Modern reviews and current emergency guidance continue to emphasize supportive treatment.

Because the toxins impair neurotransmission rather than causing irreversible destruction in most survivors, patients can recover fully if oxygenation and ventilation are maintained during the paralytic period.

Role of Anticholinesterases

Because some α-conotoxins interfere with nicotinic acetylcholine receptors, anticholinesterase therapy has occasionally been proposed theoretically. However, there is no established evidence supporting routine use of neostigmine, pyridostigmine, or related agents for cone-snail envenomation.

They should not be considered substitutes for respiratory support.

Enhanced Elimination

There is no established role for:

• Hemodialysis
• Hemoperfusion
• Plasma exchange
• Forced diuresis

in removing injected conopeptides after cone-snail envenomation.

Treatment remains supportive.

Observation

There is no rigorously validated universal observation period because severe envenomation is rare. Historically, systemic symptoms tend to evolve during the first several hours.

A patient with a credible sting from a potentially dangerous cone snail should therefore undergo observation with serial neurologic and respiratory examinations even if initially well.

The old 4–6 hour observation concept may be reasonable as a minimum for a clearly asymptomatic minor exposure, but it should not function as an automatic discharge rule when:

• Species is high risk or unknown
• The snail was large
• Neurologic symptoms occurred
• The patient has respiratory complaints
• Access to emergency care is limited

Admission

Hospital admission is appropriate for any patient with systemic neurologic symptoms, including spreading numbness, ptosis, visual disturbance, dysarthria, dysphagia, generalized weakness, or respiratory symptoms.

Patients with progressive weakness or respiratory impairment require high-acuity monitoring, usually in an ICU or equivalent setting.

Current Queensland guidance recommends urgent consultation and retrieval for suspected clinically important cone-shell envenomation with ongoing neurologic and respiratory monitoring.

Discharge

A patient may be considered for discharge only when:

• No systemic neurologic features have developed during an adequate period of observation
• Respiratory function is normal
• Local symptoms are mild or improving
• The patient can ambulate safely
• Reliable return precautions and access to care are available

A patient who developed systemic paralysis should remain hospitalized until neuromuscular and respiratory function have clearly recovered.

Prognosis

Most reported cone-snail stings are nonfatal, particularly those caused by worm- or mollusk-eating species. However, C. geographus can cause rapidly fatal paralysis, and historical case compilations contain more than 30 deaths.

Modern emergency care substantially improves survival because even profound paralysis can be supported with mechanical ventilation until venom effects resolve.

Local numbness or discomfort may persist longer than the systemic illness, while severe survivors can require prolonged recovery of strength.

Prevention

The most effective preventive advice is:

Never handle a live cone snail with bare hands.

Colorful or patterned cone shells should be treated as potentially venomous, particularly in tropical Indo-Pacific waters. Gloves do not guarantee protection because the harpoon-like radular tooth may penetrate some materials.

Do not place a live cone shell in:

• A pocket
• Clothing
• A bag held against the body

and do not handle one simply because the animal appears withdrawn into its shell.

A shell collector should use tools rather than fingers when identification is uncertain.

Important Pitfalls

A major historical error is assuming that human respiratory paralysis is unreported. In fact, progressive respiratory-muscle paralysis is the principal lethal complication of severe cone-snail envenomation.

Another pitfall is relying on local pain severity. A potentially dangerous envenomation may begin with relatively little pain, so the absence of dramatic local injury does not exclude severe systemic poisoning.

Hot-water immersion should not replace modern first aid. Current Australian guidance specifically recommends pressure immobilization for cone-shell envenomation, while hot-water immersion is used for different marine envenomations such as stonefish.

Do not wait for hypoxemia before recognizing respiratory paralysis. A patient can initially maintain oxygen saturation while ventilation and respiratory muscle strength are progressively deteriorating.

Do not assume a motionless patient is unconscious. Severe neuroparalysis may occur with preserved awareness, and communication/reassurance should continue.

The historical claim that C. tulipa is categorically the most toxic cone snail is also misleading. In human clinical experience, C. geographus is overwhelmingly the species associated with fatal envenomation.

Finally, there is no antivenom. Searching for an antidote should never delay the intervention that saves lives:

Ventilation.

High-Yield Toxicology Pearls

Cone-snail envenomation is a neuroparalytic marine emergency. More than 900 cone-snail species are now recognized, but the greatest human danger comes from large fish-hunting species, especially Conus geographus. Historical reviews document more than 30 fatalities, probably almost entirely from the geography cone.

Cone snails inject venom using a disposable harpoon-like radular tooth. Their venom is a complex mixture of conopeptides rather than a single toxin. Important families include α-conotoxins affecting nicotinic receptors, ω-conotoxins blocking calcium channels, μ-conotoxins blocking sodium channels, and κ-conotoxins affecting potassium channels.

The clinical progression is typically sting → local pain/numbness → spreading paresthesias → cranial/bulbar symptoms → generalized weakness → flaccid paralysis → respiratory failure. Perioral tingling, ptosis, blurred vision, dysarthria, and dysphagia are important warning signs.

Human respiratory paralysis is well documented and represents the major lethal mechanism. The patient may remain completely conscious while unable to move or breathe.

First aid is pressure immobilization and complete immobilization of the patient, not routine hot-water immersion. The limb should be bandaged firmly and splinted, and unnecessary movement should be avoided.

There is no antivenom and no proven pharmacologic antidote. Severe paralysis is treated with bag-mask ventilation followed by intubation and mechanical ventilation when necessary. Patients can recover if ventilation is sustained until toxin effects resolve.

Systemic neurologic symptoms require hospital admission and close respiratory monitoring. Asymptomatic minor stings may be observed and discharged if no systemic manifestations develop, but a rigid 4–6-hour discharge rule should not override species, exposure, or clinical-risk considerations.

The single most important clinical pearl is:

Cone snail + progressive weakness = anticipate respiratory paralysis before the patient becomes hypoxic.

Toxicology – Colchicine

Core Concept

Colchicine is a potent microtubule-disrupting alkaloid with a narrow therapeutic index. Severe poisoning is characterized by an initially gastrointestinal illness followed by rapidly progressive multiorgan failure, cardiovascular collapse, bone-marrow suppression, respiratory failure, coagulopathy, and sepsis.

A useful toxicologic sequence is:

Colchicine → tubulin binding → failure of microtubule polymerization → impaired mitosis and intracellular transport → GI mucosal injury + myocardial dysfunction + bone-marrow suppression + multiorgan failure

The typical clinical progression is triphasic: severe gastroenteritis during the first day, systemic organ failure over the next several days, and—if the patient survives—marrow recovery, rebound leukocytosis, and alopecia after approximately one week.

There is currently no commercially available specific antidote. Treatment requires early recognition, gastrointestinal decontamination when appropriate, aggressive intensive supportive care, and serial surveillance for delayed marrow failure.

Current Forms and Uses

Modern colchicine is principally administered orally. U.S. formulations include 0.6-mg tablets and capsules, while the cardiovascular product LODOCO contains 0.5 mg. Current indications include treatment and prophylaxis of gout flares and familial Mediterranean fever. Colchicine also has specialist uses in inflammatory diseases and pericarditis, while low-dose colchicine 0.5 mg daily is now approved in the United States to reduce cardiovascular events in adults with established atherosclerotic disease or multiple cardiovascular risk factors.

The historical practice of treating acute gout with 0.6 mg every hour until diarrhea or a cumulative 6 mg is obsolete and dangerous. The current FDA-labeled regimen for an acute gout flare is 1.2 mg initially followed by 0.6 mg one hour later, for a total of 1.8 mg, because higher doses provide no additional efficacy and substantially increase adverse effects.

Intravenous colchicine should also be regarded as historical in the United States. FDA took enforcement action in February 2008 to remove unapproved injectable colchicine products from the market because of the drug’s narrow therapeutic margin and the danger of fatal dosing errors with intravenous administration.

Plant Sources

Colchicine occurs naturally in Colchicum autumnale, commonly called autumn crocus or meadow saffron, and in Gloriosa superba, commonly called glory lily or flame lily. All portions of these plants can be toxic. Gloriosa tubers and seeds contain substantial amounts of colchicine and related alkaloids, while accidental Colchicum autumnale poisoning has occurred when leaves are mistaken for edible wild plants such as wild garlic.

Plant poisoning can be every bit as severe as pharmaceutical colchicine poisoning. A large Sri Lankan series of Gloriosa superba self-poisoning reported approximately 10% mortality, demonstrating that the older claim that plant intoxication is usually less severe is incorrect.

Mechanism of Toxicity

Colchicine binds to tubulin and prevents normal polymerization of microtubules. Because microtubules are necessary for mitosis, vesicular transport, maintenance of cellular structure, leukocyte movement, and many other cellular processes, colchicine toxicity affects far more than simply cell division.

Rapidly proliferating tissues are particularly vulnerable, including the gastrointestinal epithelium, bone marrow, and hair follicles, explaining the characteristic progression from gastroenteritis to pancytopenia and later alopecia. Myocardial and neuromuscular tissues can also be severely affected because microtubule disruption interferes with cellular transport, electrophysiology, contractility, and energy metabolism.

Pharmacokinetics

Colchicine is absorbed relatively rapidly after oral ingestion, with peak concentrations after ordinary therapeutic doses occurring at approximately one hour. It undergoes significant hepatic metabolism and biliary excretion, as well as renal elimination. It is a substrate for both CYP3A4 and P-glycoprotein (P-gp) and undergoes enterohepatic recirculation.

These characteristics help explain why toxicity may be prolonged and why drug interactions are so important. Colchicine also has extensive tissue distribution, which is one reason extracorporeal removal is ineffective once systemic absorption has occurred.

Drug Interactions

Modern understanding of colchicine interactions is substantially different from the older emphasis on cimetidine and tolbutamide. The most important interactions involve inhibitors of:

CYP3A4 and P-glycoprotein

Important examples include clarithromycin, erythromycin, azole antifungals, cyclosporine, several HIV protease inhibitors, and other strong CYP3A4/P-gp inhibitors. These drugs can markedly increase colchicine exposure and have produced life-threatening or fatal toxicity even when colchicine itself was prescribed at therapeutic doses.

The combination is particularly dangerous in patients with renal or hepatic impairment. Current colchicine labeling contraindicates coadministration of strong CYP3A4 or P-gp inhibitors with colchicine in patients with renal or hepatic impairment because fatal interactions have occurred.

FDA’s review of historical colchicine deaths found that a substantial proportion of non-overdose fatalities involved drug interactions, with clarithromycin especially prominent.

Statins and Myotoxicity

Colchicine can itself cause neuromyopathy and rhabdomyolysis, particularly when accumulation occurs. Concomitant statins, fibrates, cyclosporine, and other myotoxic medications can increase this risk. Current labeling reports myopathy and rhabdomyolysis—including fatal cases—with colchicine and HMG-CoA reductase inhibitors.

Therefore, weakness or muscle pain in a patient receiving colchicine should not automatically be attributed to gout, age, or deconditioning.

Renal and Hepatic Impairment

Renal and hepatic dysfunction both increase the risk of colchicine accumulation and toxicity. Current dosing must be modified according to renal function, hepatic function, indication, and concomitant interacting medications. Severe renal impairment requires markedly reduced prophylactic dosing and prolonged intervals between treatment courses.

The important toxicology principle is that:

Therapeutic dosing can become toxic when clearance is impaired.

Therefore a patient can have severe colchicine poisoning without a deliberate overdose.

Toxic Dose

Colchicine has a notoriously narrow therapeutic margin. Historically, oral exposures have been divided into approximate risk categories of <0.5 mg/kg, 0.5–0.8 mg/kg, and >0.8 mg/kg. Early reports suggested little mortality below 0.5 mg/kg, significant toxicity between 0.5 and 0.8 mg/kg, and near-universal mortality above 0.8 mg/kg.

These categories remain useful as rough risk markers but should not be treated as reliable outcome thresholds. Modern case reports document critical illness after doses well below 0.5 mg/kg, including severe multiorgan poisoning after approximately 0.2 mg/kg, while survival has occurred after doses historically classified as lethal.

Thus:

There is no absolute “safe” or inevitably fatal colchicine dose.

Any substantial overdose deserves aggressive assessment, and symptoms matter more than a historical dose cutoff.

Clinical Course

Colchicine poisoning is classically divided into three overlapping phases. This triphasic description is useful clinically but should not be interpreted as an exact timetable.

Phase 1 – Gastrointestinal Toxicity

The first phase usually develops within the first several hours and predominates during approximately the first 24 hours. Patients develop nausea, profuse vomiting, severe abdominal pain, and watery diarrhea, sometimes with gastrointestinal bleeding.

The syndrome can resemble severe gastroenteritis or cholera and may cause profound volume depletion, electrolyte abnormalities, metabolic acidosis, and early hypotension. Leukocytosis is common during this stage.

Importantly, the gastrointestinal symptoms are not simply benign adverse effects. In a significant overdose they represent direct gastrointestinal cellular injury and can be the first warning of impending systemic toxicity.

Phase 2 – Multiorgan Failure

The second phase typically becomes apparent after approximately 24 hours and may continue for several days. This is the life-threatening phase, characterized by progressive dysfunction of the cardiovascular, hematologic, respiratory, hepatic, renal, neurologic, and muscular systems.

Patients may develop shock, myocardial depression, ventricular dysrhythmias, ARDS, renal and hepatic injury, disseminated intravascular coagulation, encephalopathy, seizures, rhabdomyolysis, and profound bone-marrow suppression. Death during this phase is commonly caused by cardiovascular collapse, respiratory failure, or progressive multiorgan failure.

Phase 3 – Recovery

Patients who survive the period of multiorgan dysfunction generally enter a recovery phase beginning around day 7 or later. Bone marrow activity returns, often producing rebound leukocytosis, and alopecia may appear as damaged hair follicles enter recovery.

Weakness, neuropathy, and myopathy may persist for weeks, but survivors can eventually make a substantial or complete recovery if irreversible hypoxic or organ injury has not occurred.

Gastrointestinal Toxicity

Nausea, vomiting, abdominal cramping, and diarrhea are usually the earliest symptoms. Severe fluid losses can produce hypovolemic shock, renal hypoperfusion, metabolic acidosis, and major electrolyte abnormalities.

The onset of diarrhea after therapeutic colchicine is also an important warning sign. Because gastrointestinal effects are dose-related, new significant diarrhea in a patient receiving colchicine—particularly with renal disease or interacting medications—should trigger immediate review of dosing and toxicity risk.

Cardiovascular Toxicity

Cardiovascular failure is one of the most important causes of early death. Colchicine can produce myocardial dysfunction, reduced contractility, conduction abnormalities, dysrhythmias, and refractory shock. Patients may initially be tachycardic from dehydration and physiologic stress but later develop severe pump failure and vasoplegia.

ECG abnormalities can include conduction disturbances and nonspecific ST-T changes. Troponin elevation may occur with myocardial injury. Bedside echocardiography is particularly useful in severe poisoning to distinguish hypovolemia, vasodilatory shock, and cardiogenic myocardial depression.

Pulmonary Toxicity

Severe poisoning may progress to acute respiratory failure and ARDS. Respiratory failure can reflect pulmonary edema, systemic inflammation, neuromuscular weakness, aspiration, cardiovascular collapse, or a combination of these processes.

Patients with increasing oxygen requirements, altered consciousness, or progressive shock require early critical-care involvement and may need lung-protective mechanical ventilation.

Hematologic Toxicity

A characteristic feature of significant colchicine poisoning is delayed bone-marrow suppression. Early leukocytosis may be followed by leukopenia, neutropenia, thrombocytopenia, anemia, and potentially pancytopenia or aplastic marrow failure.

The nadir commonly occurs around days 3–7, although the exact timing varies. Current labeling recognizes leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, and aplastic anemia as manifestations of colchicine toxicity.

Severe poisoning may also produce disseminated intravascular coagulation and bleeding.

Neutropenic Sepsis

Once severe neutropenia develops, secondary bacterial or fungal infection can become life-threatening. Fever during this stage must never simply be attributed to colchicine toxicity.

Fever + severe neutropenia = treat as febrile neutropenia/sepsis until proven otherwise.

Broad-spectrum antimicrobial therapy should be initiated promptly according to contemporary febrile-neutropenia protocols after appropriate cultures, without delaying treatment for microbiologic confirmation.

G-CSF

Granulocyte colony-stimulating factor, such as filgrastim, has been used in severe colchicine-induced neutropenia and marrow suppression. Published case series report accelerated recovery of neutrophil counts, but controlled outcome evidence is limited.

Therefore G-CSF is reasonable to consider in severe poisoning with substantial neutropenia, particularly febrile neutropenia, after hematology/toxicology consultation. It should be considered an adjunct rather than a colchicine antidote.

Hepatic Toxicity

Significant colchicine poisoning can produce hepatocellular injury with rising aminotransferases, bilirubin abnormalities, and impaired synthetic function. Prolonged INR may reflect both hepatic injury and disseminated intravascular coagulation.

Severe hepatic dysfunction generally occurs in the setting of broader multiorgan poisoning rather than isolated liver toxicity.

Renal Toxicity

Acute kidney injury may result from several mechanisms including severe dehydration, shock, rhabdomyolysis, multiorgan failure, and direct cellular toxicity. Urinalysis may reveal hematuria, proteinuria, or myoglobinuria.

Renal failure is particularly important because impaired colchicine clearance can further prolong systemic exposure.

Muscular and Neurologic Toxicity

Colchicine can produce myopathy, rhabdomyolysis, peripheral neuropathy, weakness, and hyporeflexia. Neuromuscular toxicity is particularly recognized during chronic therapeutic accumulation in patients with renal impairment or interacting medications, but it can also occur during major acute poisoning.

Severe acute poisoning may produce confusion, delirium, seizures, coma, and profound weakness. Neurologic abnormalities should also trigger evaluation for hypoxia, electrolyte disturbances, hypoglycemia, sepsis, and other causes.

Alopecia

Hair loss is a classic delayed finding and usually becomes apparent about one to several weeks after substantial poisoning. It reflects interruption of mitosis in rapidly dividing hair-follicle cells and is typically reversible in survivors.

Alopecia appearing during recovery can therefore retrospectively strengthen the diagnosis of significant colchicine exposure.

Diagnosis

Diagnosis is usually clinical and is based on known or suspected exposure combined with the characteristic progression from gastroenteritis to multiorgan dysfunction and marrow suppression.

Important clues include access to colchicine medication, treatment for gout or FMF, recent prescription of a CYP3A4/P-gp inhibitor, renal impairment, or ingestion of Colchicum autumnale or Gloriosa superba.

The differential includes iron poisoning, salicylate poisoning, arsenic, organophosphate or carbamate poisoning, toxic mushrooms or plants, severe infectious gastroenteritis, sepsis, and other cytotoxic or antimitotic agents.

Laboratory Evaluation

All significant exposures require serial laboratory testing rather than a single reassuring initial panel. Appropriate studies include CBC with differential and platelets, electrolytes, bicarbonate, glucose, BUN, creatinine, magnesium, calcium, liver enzymes, bilirubin, PT/INR, aPTT, fibrinogen, CK, lactate, and urinalysis.

Severe poisoning warrants blood-gas analysis, type and crossmatch, serial coagulation studies, and frequent assessment for hypoglycemia, acidosis, rhabdomyolysis, hepatic failure, and evolving marrow suppression.

The CBC is especially important because the initial leukocytosis can create false reassurance before a later precipitous decline in leukocytes and platelets.

ECG and Cardiac Assessment

An ECG and continuous cardiac monitoring are appropriate for significant poisoning. Serial ECGs should be obtained when hemodynamic instability or conduction abnormalities develop.

In severe shock, cardiac biomarkers and bedside echocardiography can help identify myocardial dysfunction. Persistent or worsening cardiogenic shock despite conventional treatment should prompt early discussion with a center capable of advanced mechanical circulatory support.

Colchicine Concentrations

The old statement that colchicine concentrations are completely useless requires nuance. Specialized quantitative colchicine testing is not routinely available rapidly enough to guide emergency management and there is no widely validated therapeutic decision threshold, so initial treatment should never wait for a level.

However, research involving Gloriosa superba poisoning found that admission plasma colchicine concentrations correlated strongly with mortality. Thus, concentrations can have toxicokinetic or prognostic value in specialized settings even though they remain impractical for routine bedside management.

Initial Treatment

Any significant colchicine overdose should be discussed early with a poison center or medical toxicologist. Patients with substantial intentional ingestion, severe gastrointestinal symptoms, hemodynamic abnormalities, laboratory abnormalities, or uncertain high-risk doses require hospital admission, usually to a high-acuity monitored setting.

The patient can initially look relatively well while irreversible intracellular toxicity is developing. Early aggressive care is therefore preferable to waiting for overt multiorgan failure.

Airway and Breathing

Airway management should follow standard critical-care principles. Intubation is appropriate for coma, respiratory failure, severe aspiration risk, or progressive shock with inability to maintain adequate ventilation.

ARDS should be managed with lung-protective ventilation and appropriate PEEP.

Circulation and Shock

Early shock may reflect profound gastrointestinal fluid loss, and isotonic crystalloid should be administered when hypovolemia is present. Severe cases often progress to mixed distributive and cardiogenic shock, so further fluids should be guided by examination, ultrasound, hemodynamics, and response rather than indiscriminate large-volume administration.

Persistent shock generally requires norepinephrine, with additional vasoactive or inotropic support individualized to cardiac function. Echocardiography can help identify severe myocardial depression.

Rare patients with otherwise refractory cardiogenic or mixed shock have been managed with extracorporeal life support. This remains rescue therapy for selected catastrophic cases rather than routine treatment.

Gastrointestinal Decontamination

Induced Emesis

Do not induce vomiting and do not use ipecac.

The old recommendation to induce emesis within 30 minutes is obsolete. These patients frequently vomit spontaneously, can deteriorate rapidly, and are at risk for aspiration.

Activated Charcoal

Colchicine is adsorbed by activated charcoal, so single-dose activated charcoal should be considered after a recent potentially serious oral ingestion when the airway is intact or protected. The greatest expected benefit is early after ingestion. Routine charcoal in every patient is not supported, and it is contraindicated when the airway is unprotected.

Because colchicine undergoes enterohepatic recirculation, multiple-dose activated charcoal (MDAC) has a plausible pharmacokinetic rationale and is sometimes used after severe poisoning. However, controlled evidence that MDAC reduces mortality is lacking, and general toxicology guidelines have not established colchicine as one of the classic evidence-supported MDAC indications.

Thus MDAC should be viewed as a specialist-directed adjunct in major poisoning, provided bowel function and airway safety permit it.

Gastric Lavage

Several older colchicine reviews and even some current product labels continue to recommend gastric lavage after severe recent ingestion. However, modern toxicology position statements conclude that gastric lavage should not be performed routinely, if at all, because clinical benefit is unproven and serious complications can occur.

Only an extraordinary, immediately life-threatening, very recent ingestion could justify lavage after airway protection and consultation with an experienced medical toxicologist. It should not be a routine response to colchicine overdose.

Antidote

There is currently no commercially available specific antidote for colchicine poisoning.

Supportive critical care remains the standard treatment.

Colchicine-Specific Fab Fragments

Colchicine-specific antibody Fab fragments represent a genuine potential antidotal strategy. A landmark human case described dramatic improvement after administration of colchicine-specific Fab in a patient with otherwise extremely severe poisoning.

Animal models also demonstrate effective binding and redistribution of colchicine. However:

Colchicine-specific Fab fragments are not commercially available for routine clinical use.

They should therefore be regarded as an experimental antidote rather than something an emergency department can ordinarily obtain. Contemporary reviews continue to identify Fab development as an important future therapeutic strategy.

Hemodialysis

Hemodialysis does not effectively remove colchicine.

Colchicine has extensive tissue distribution and rapidly leaves the vascular compartment. Current prescribing information specifically states that colchicine is not effectively removed by dialysis.

Therefore dialysis should not be initiated simply to enhance colchicine elimination.

It remains appropriate for conventional indications such as refractory hyperkalemia, severe metabolic acidosis, volume overload, or severe kidney failure. In such situations dialysis is treating the complications of poisoning rather than substantially clearing colchicine.

Hemoperfusion, Plasma Exchange, and Other Extracorporeal Techniques

Hemoperfusion, plasma exchange, hemofiltration, and related extracorporeal approaches have been reported in severe cases, but evidence is limited to case reports and small series. Because colchicine rapidly distributes into tissues, these methods are not established antidotal treatments.

They may sometimes be used as part of multiorgan supportive care or experimental rescue strategies, but clinicians should not expect reliable toxin clearance.

Rhabdomyolysis

Rhabdomyolysis should be treated with adequate IV crystalloid, correction of electrolyte abnormalities, and management of the underlying shock or hyperthermia. Serial CK, potassium, calcium, creatinine, and urine output should be monitored.

Routine urine alkalinization is not an established colchicine treatment.

Coagulopathy and Bleeding

Severe disseminated intravascular coagulation may require blood-product support according to bleeding, fibrinogen concentration, platelet count, and coagulation status. Packed red blood cells, platelets, cryoprecipitate, and plasma should be used according to standard critical-care/transfusion indications rather than prophylactically solely because colchicine was ingested.

Infection Management

The risk of infection rises substantially when neutropenia develops. Cultures should be obtained when infection is suspected, but broad-spectrum antibiotics should not be delayed in a hemodynamically unstable or febrile neutropenic patient.

Routine prophylactic antibiotics for every early colchicine ingestion are not established. Therapy should be driven by neutropenia, fever, documented infection, or standard ICU infectious indications.

Plant Poisoning Management

Poisoning from Colchicum autumnale or Gloriosa superba should be managed according to the same principles as pharmaceutical colchicine poisoning. Do not assume a natural product is milder.

When plant material is available, preserve it for botanical identification. Accidental Colchicum autumnale ingestion can occur when leaves are mistaken for wild garlic or other edible plants, while Gloriosa superba tuber ingestion may be intentional in regions where the plant is readily available.

Pregnancy

The old FDA Pregnancy Category D system is obsolete, and the statement that therapeutic colchicine is associated with Down syndrome or “trisomy 23” should not be carried forward.

Current labeling states that decades of published human experience with therapeutic colchicine during pregnancy have not identified an increased risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes, although colchicine crosses the placenta and animal studies demonstrate developmental toxicity at sufficient exposures.

In acute overdose, maternal resuscitation and treatment of shock, hypoxemia, multiorgan failure, and electrolyte abnormalities take priority.

Breastfeeding

The old implication that breastfeeding should generally be avoided is also outdated for therapeutic colchicine use. Colchicine enters breast milk, but LactMed reports that maternal doses up to approximately 1.5 mg/day result in an infant exposure below 10% of the maternal weight-adjusted dose, and published studies have not identified adverse effects in breastfed infants. Many expert guidelines consider therapeutic colchicine compatible with breastfeeding.

This therapeutic evidence should not be extrapolated to a mother with acute colchicine overdose. Breastfeeding decisions during significant maternal poisoning require individualized toxicology and pediatric assessment.

Observation

A known significant overdose should not be discharged after a short symptom-free interval simply because the patient initially appears well. Gastrointestinal manifestations may be delayed for several hours and systemic deterioration can become evident during the following day.

The older 24-hour asymptomatic observation rule is safer than a short ED observation period but should still be individualized. Because of the potentially catastrophic delayed course, deliberate or uncertain substantial ingestions generally warrant prolonged observation with serial laboratory testing and toxicology consultation.

Admission

Hospital admission is appropriate for any patient with significant intentional overdose, substantial plant ingestion, gastrointestinal symptoms, metabolic abnormalities, cardiovascular abnormalities, renal or hepatic dysfunction, or an uncertain potentially serious dose.

ICU admission is appropriate for severe vomiting/diarrhea with major fluid loss, hypotension, metabolic acidosis, myocardial dysfunction, dysrhythmia, respiratory failure, significant coagulopathy, evolving multiorgan failure, or severe neurologic toxicity.

Monitoring

Patients with serious poisoning require continuous cardiac and respiratory monitoring together with frequent assessment of hemodynamics and urine output. Serial CBC with differential, platelet count, electrolytes, renal function, liver function, coagulation studies, lactate, CK, and acid-base status are essential.

Importantly, monitoring must continue after the gastrointestinal symptoms improve because marrow suppression often worsens after the patient appears to be recovering from the initial GI illness.

Prognosis

Prognosis depends on dose, timing of treatment, age, renal and hepatic function, drug interactions, and the severity of early systemic abnormalities. Severe acidosis, cardiovascular collapse, coagulopathy, progressive organ failure, and major marrow suppression are concerning findings.

Historical dose-response estimates are useful only for broad risk assessment. A patient who has ingested less than 0.8 mg/kg can still become critically ill, while survival above this traditional “lethal” dose is possible with intensive care.

Patients who survive the first several days and demonstrate marrow and cardiovascular recovery often ultimately recover, although prolonged weakness, neuropathy, myopathy, renal dysfunction, or complications of hypoxia and sepsis may persist.

Important Pitfalls

A major pitfall is using the historical gout regimen of repeated hourly colchicine until diarrhea develops. Diarrhea is a sign of toxicity, not a therapeutic endpoint. Current acute-gout treatment is only 1.8 mg total over one hour.

Another important error is believing that only deliberate massive overdoses cause fatal colchicine toxicity. Therapeutic doses can become life-threatening when combined with CYP3A4 or P-gp inhibitors, particularly in renal or hepatic impairment. Clarithromycin is a classic example.

The historical 0.5- and 0.8-mg/kg thresholds should not be interpreted as guarantees of survival or death. Severe poisoning has occurred below these ranges.

An early leukocytosis should not reassure the clinician. Colchicine poisoning can subsequently produce profound leukopenia and pancytopenia several days later.

Improvement in vomiting and diarrhea does not necessarily mean the poisoning is resolving. The patient may be transitioning from gastrointestinal toxicity into the multiorgan-failure phase.

Routine ipecac and gastric lavage are obsolete. Activated charcoal is the more reasonable decontamination strategy after a recent substantial exposure when the airway is safe, with MDAC considered selectively rather than automatically.

Another major pitfall is starting hemodialysis simply to remove colchicine. Dialysis does not meaningfully clear the drug after tissue distribution.

Finally, colchicine-specific Fab fragments are a promising genuine antidotal concept, but they remain experimental and unavailable for routine clinical treatment.

High-Yield Toxicology Pearls

Colchicine poisoning should be remembered as “GI catastrophe first, multiorgan failure second, marrow recovery and alopecia later.” The drug binds tubulin and disrupts microtubules, damaging rapidly dividing tissues as well as myocardium, muscle, and other organs.

Current acute gout therapy is 1.2 mg followed by 0.6 mg one hour later, not repeated hourly dosing until diarrhea. Oral colchicine has a very narrow therapeutic margin, and CYP3A4/P-gp inhibitors—especially clarithromycin and cyclosporine—can cause fatal accumulation even during therapeutic dosing.

Historical dose categories of <0.5 mg/kg, 0.5–0.8 mg/kg, and >0.8 mg/kg are only rough prognostic markers. Severe toxicity can occur below 0.5 mg/kg, and no dose guarantees a particular outcome.

The early phase produces vomiting, abdominal pain, profuse diarrhea, dehydration, and leukocytosis. The dangerous second phase produces cardiovascular collapse, ARDS, hepatic and renal injury, DIC, rhabdomyolysis, neurologic toxicity, and bone-marrow suppression. Neutrophils and platelets may reach their nadir around days 3–7.

Serial CBC and multiorgan laboratory monitoring are therefore essential even after gastrointestinal symptoms improve. Fever during severe neutropenia should be treated as febrile neutropenia/sepsis, and G-CSF may be considered for severe marrow suppression.

There is no commercially available antidote. Colchicine-specific Fab fragments have produced dramatic benefit experimentally and in a rare human case but remain unavailable for routine clinical use.

Activated charcoal should be considered early after a significant ingestion when the airway is safe. Ipecac is obsolete, routine gastric lavage is not recommended, and multiple-dose charcoal remains a specialist-directed option with limited outcome evidence.

Colchicine is not effectively removed by hemodialysis because of extensive tissue distribution. Dialysis should be used for standard renal/metabolic indications rather than as a toxin-removal strategy.

Plant poisoning from Colchicum autumnale and Gloriosa superba can be severe or fatal and should be treated exactly as pharmaceutical colchicine poisoning.

The old Pregnancy Category D classification is obsolete. Therapeutic human pregnancy data do not demonstrate an increased major congenital-malformation or miscarriage risk, and therapeutic colchicine is generally considered compatible with breastfeeding.

The most important clinical warning is:

Severe gastroenteritis after colchicine exposure may be the beginning—not the peak—of the poisoning.

Toxicology – Cocaine “Washed-Out” Syndrome

Core Concept

The historical term “cocaine washed-out syndrome” describes marked somnolence or depressed mental status following prolonged or binge cocaine use. In modern terminology, this presentation is better considered part of the acute stimulant crash/withdrawal spectrum rather than a distinct toxicologic syndrome.

A typical stimulant crash consists of exhaustion, hypersomnolence, fatigue, dysphoria, increased appetite, and psychomotor slowing after prolonged stimulant use and sleep deprivation. Current ASAM/AAAP guidance notes that many patients experience approximately 12–24 hours of somnolence and irritability after abrupt reduction or cessation of stimulant use, probably reflecting both catecholaminergic adaptation and accumulated sleep deprivation.

The crucial modern point is:

Profound coma should never automatically be attributed to a cocaine “crash.”

True unresponsiveness requires exclusion of opioid or sedative coexposure, hypoglycemia, hypoxia, hypercapnia, stroke, intracranial hemorrhage, trauma, seizure/postictal state, infection, metabolic abnormalities, and other causes.

Terminology

“Washed-out syndrome” is largely a historical emergency-medicine term and is not commonly used as a formal contemporary diagnostic category. Current guidelines instead describe stimulant withdrawal, whose acute manifestations include hypersomnolence, fatigue, irritability, depression, altered appetite, and psychomotor changes.

Classic cocaine-withdrawal symptoms include dysphoric mood, fatigue, vivid unpleasant dreams, insomnia or hypersomnia, increased appetite, and psychomotor retardation or agitation.

Thus, a better conceptual sequence is:

Repeated cocaine/stimulant use + prolonged wakefulness → stimulant cessation → crash → hypersomnolence + exhaustion + dysphoria

rather than assuming that cocaine directly produces a delayed pharmacologic coma.

Pathophysiology

The older explanation attributed the syndrome simply to catecholamine depletion after repeated cocaine exposure. That concept remains plausible but is incomplete. Modern understanding emphasizes a combination of neuroadaptation to repeated dopaminergic and adrenergic stimulation, changes in reward circuitry, acute withdrawal, and profound sleep debt accumulated during stimulant binges.

ASAM/AAAP specifically notes that early somnolence after stimulant cessation is likely related to both catecholamine depletion and sleep deprivation.

The depressed mental state is therefore often physiologically different from the respiratory and CNS depression produced by opioids, benzodiazepines, or barbiturates.

Typical Time Course

After cessation of a binge, many patients enter an early “crash” characterized by overwhelming tiredness and increased sleep. Current guidance describes 12–24 hours of prominent somnolence and irritability in many patients, although the broader withdrawal syndrome can continue for days.

Subsequent symptoms may include depression, anxiety, insomnia, paranoia, and other psychiatric complaints that can persist for weeks to months in some patients. Sleep may initially increase and later become disrupted.

The older statement that mental status should always normalize within several hours or at most 24 hours is therefore too rigid. Profound coma lasting many hours, however, remains atypical and should trigger renewed diagnostic evaluation.

Clinical Features

The most typical patient is profoundly tired after repeated stimulant use and may sleep for prolonged periods. Mental status may range from lethargy to marked somnolence, but the patient should generally maintain stable ventilation, oxygenation, and hemodynamics unless another complication or coexposure exists.

Vital signs may be normal or may show residual effects of recent stimulant use, such as mild tachycardia or hypertension. Later withdrawal can occasionally be associated with relative bradycardia. Pupils are not reliably diagnostic and may be normal or mid-position.

There should be no persistent focal neurologic deficit attributable simply to stimulant withdrawal. Hemiparesis, aphasia, gaze deviation, severe headache, meningismus, or asymmetric examination findings require evaluation for an alternative neurologic diagnosis.

Why Deep Coma Is a Red Flag

Contemporary stimulant-withdrawal guidance describes somnolence, not unexplained deep coma, as the characteristic acute neurologic finding.

Therefore, a patient who cannot be awakened, does not protect the airway, has significant hypoventilation, or has a Glasgow Coma Scale markedly below normal should not simply be labeled “washed out.”

The differential should remain broad until serious causes have been excluded.

Opioid Coexposure – Major Modern Pitfall

This is perhaps the most important change from the original chapter.

Modern illicit cocaine is often used with or contaminated by other substances, particularly illegally manufactured fentanyl and other opioids. CDC notes that polysubstance exposure involving cocaine and opioids is common, and in 2021 approximately 78.6% of U.S. cocaine-involved overdose deaths also involved an opioid.

Therefore:

Cocaine history + coma or respiratory depression ≠ cocaine crash until opioid toxicity has been considered.

Findings such as bradypnea, apnea, marked miosis, low oxygen saturation, or rising CO₂ should prompt immediate treatment as possible opioid poisoning.

Naloxone

Naloxone does not reverse cocaine withdrawal itself. However, because opioid coexposure is common and may be unintentional:

Give naloxone promptly when opioid toxicity cannot be excluded and respiratory depression is present.

Naloxone is safe and effective for opioid overdose, including fentanyl, but it will not reverse isolated cocaine effects.

Airway support and ventilation should never be delayed while waiting to see whether naloxone works.

Other Important Differential Diagnoses

Other toxicologic causes of depressed consciousness include opioids, alcohol, benzodiazepines, barbiturates, GHB, clonidine, antipsychotics, sedating anticonvulsants, baclofen, and mixed drug overdose.

Medical causes include hypoglycemia, hypoxia, hypercapnia, severe electrolyte abnormalities, renal or hepatic failure, sepsis, meningitis or encephalitis, hypothyroidism, adrenal crisis, stroke, intracranial hemorrhage, head trauma, and postictal states.

Cocaine itself can cause ischemic stroke, intracranial hemorrhage, seizures, myocardial infarction, and hyperthermic multiorgan injury, so a recent cocaine binge does not make these alternative diagnoses less likely.

Cardiac Disease Can Be Hidden by Somnolence

An important historical case described myocardial infarction in a patient initially considered to have cocaine “washed-out syndrome.” Her marked hypersomnolence made assessment of ongoing chest pain difficult.

This remains clinically important. A sleepy patient following a cocaine binge can still have:

Acute coronary syndrome, myocarditis, dysrhythmia, or other cardiovascular injury.

Do not allow a benign-appearing sleeping patient to obscure evidence of serious cocaine-associated disease.

Initial Assessment

The first priorities are airway, breathing, circulation, bedside glucose, temperature, and neurologic examination.

Assess respiratory rate and depth rather than relying solely on oxygen saturation. A patient receiving supplemental oxygen can remain well saturated while developing severe hypercapnia. Capnography is useful when ventilation is uncertain.

Examine for trauma, injection marks, focal neurologic findings, meningismus, hyperthermia, muscle rigidity, and evidence of prolonged immobilization.

Laboratory Evaluation

Testing should be guided by the presentation rather than performed automatically in every mildly sleepy patient. Current ASAM/AAAP guidance recommends symptom-directed testing and identifies CBC, metabolic testing, liver tests, CK/lactate when muscle injury or acidosis is suspected, and cardiac biomarkers when myocardial injury is a concern.

At minimum, significant unexplained depressed consciousness generally warrants bedside glucose, electrolytes, renal function, and an ECG. Additional testing may include liver enzymes, CK, lactate, blood gas, troponin, CBC, urinalysis, and pregnancy testing according to the clinical setting.

In an intentional or uncertain overdose, acetaminophen and salicylate concentrations remain appropriate when occult coingestion is possible.

Blood Gas and Capnography

The old recommendation for routine arterial blood gas analysis in every case is unnecessary. A venous or arterial blood gas is useful when there is:

Hypoventilation, unexplained acidosis, significant hypoxemia, severe systemic illness, or uncertain respiratory status.

Capnography is particularly valuable when respiratory depression from a possible opioid or sedative coexposure is suspected.

Routine methemoglobin measurement is unnecessary unless the clinical presentation specifically suggests methemoglobinemia.

Urine Drug Screening

A positive cocaine urine test generally reflects detection of the metabolite benzoylecgonine and proves only recent exposure. It does not show that cocaine is responsible for the patient’s current coma.

Similarly, standard opioid immunoassays may fail to detect fentanyl, depending on the assay used. Therefore a negative routine “opiate” screen must not be used to rule out fentanyl exposure.

Clinical treatment—including naloxone when appropriate—should not wait for toxicology results.

Neuroimaging

Head CT is indicated when there is concern for:

Head trauma, focal neurologic deficit, severe sudden headache, persistent unexplained coma, intracranial hemorrhage, or stroke.

Cocaine is itself a risk factor for cerebrovascular disease, so clinicians should maintain a low threshold for neuroimaging when the neurologic examination is abnormal.

Routine CT is not required for a patient with a classic, improving stimulant crash and normal neurologic examination.

Lumbar Puncture

Lumbar puncture is not routine for stimulant withdrawal. It should be performed only when there is a specific concern for meningitis, encephalitis, subarachnoid hemorrhage not adequately evaluated by imaging, or another appropriate neurologic indication.

The old approach of automatically obtaining CT, lumbar puncture, and cultures for every deeply sleepy cocaine user is unnecessarily broad; evaluation should be guided by the history and examination.

Treatment

There is no specific pharmacologic antidote for stimulant withdrawal or the cocaine crash. Current care focuses on maintaining physiologic safety, excluding dangerous alternative diagnoses, providing a calm environment, allowing restorative sleep, hydration and nutrition, and treating specific symptoms. ASAM/AAAP states that the modern standard of care for stimulant withdrawal is symptom relief and risk reduction, with environmental and behavioral measures forming an important component.

Airway and Ventilation

A genuinely somnolent withdrawal patient should ordinarily continue to breathe adequately. If ventilation or airway protection is impaired:

Support the airway rather than attributing respiratory failure to “washout.”

Provide oxygen for hypoxemia and bag-mask ventilation when needed. Intubate for persistent apnea, inadequate ventilation, inability to protect the airway, or other standard indications.

At the same time, give naloxone when opioid coexposure is plausible.

Fluids and Nutrition

Many patients have eaten, slept, and hydrated poorly during a stimulant binge. Oral fluids and nutrition are appropriate once the patient is awake and can swallow safely. IV isotonic fluid is appropriate for clinically significant dehydration or associated rhabdomyolysis.

There is no benefit to routine forced diuresis.

Stimulant Withdrawal Medication

No medication is established as a specific treatment for the acute cocaine crash. ASAM/AAAP notes that pharmacotherapies studied for general stimulant withdrawal have limited and generally low-quality evidence.

Medication should therefore target specific clinically significant problems such as persistent depression, psychosis, agitation, or insomnia rather than attempting to “reverse” withdrawal pharmacologically.

Stimulants should not simply be administered to awaken a sleeping patient who has not yet been adequately evaluated.

Psychiatric Symptoms

Withdrawal may include depressed mood, anxiety, irritability, paranoia, and sleep disturbance, and some symptoms can persist for weeks or months.

Patients presenting after stimulant intoxication or withdrawal should be assessed for suicide and self-harm risk. ASAM/AAAP specifically recommends routine assessment of suicidality because people using stimulants have an elevated risk of self-harm.

This is particularly important during the crash when euphoria abruptly gives way to exhaustion, dysphoria, anhedonia, and depression.

Gastrointestinal Decontamination

GI decontamination has no role in the ordinary cocaine “washed-out” syndrome.

The syndrome follows cessation after a binge; there is generally no relevant drug remaining in the stomach that can be removed.

Therefore:

Do not induce vomiting. Do not perform gastric lavage. Do not routinely administer activated charcoal.

Activated charcoal would only be considered if there were a separate, recent, clinically significant oral ingestion for which charcoal is otherwise indicated and the airway is intact or protected.

The old recommendation to administer charcoal merely because a patient presents after cocaine binge use should not be carried forward.

Enhanced Elimination

There is no role for:

Hemodialysis, hemoperfusion, urinary alkalinization, or forced diuresis

for stimulant withdrawal or cocaine elimination.

Management remains supportive.

Prolonged Immobilization

A very somnolent patient may remain in one position for many hours and can develop pressure injury, peripheral nerve compression, or compartment syndrome.

Patients with prolonged unresponsiveness should be examined for:

Limb swelling, tense compartments, severe pain when awake, pressure injuries, and rhabdomyolysis.

Check CK, potassium, and renal function when prolonged immobilization is substantial.

Monitoring

Patients with significant depressed consciousness should have serial assessment of:

Mental status, respiratory rate, oxygenation, ventilation, blood pressure, pulse, temperature, and glucose.

Continuous cardiac monitoring is appropriate when there is:

• Significant altered consciousness
• Chest pain
• Dysrhythmia
• Severe recent cocaine toxicity
• Important coingestion

Monitoring can be reduced once a benign stimulant crash has been established and the patient is clearly recovering.

Admission

The old recommendation that every patient must be admitted is unnecessarily rigid.

Patients with genuine coma, airway compromise, respiratory depression, persistent unexplained altered consciousness, significant cardiovascular abnormalities, serious metabolic abnormalities, stroke/trauma concerns, rhabdomyolysis, or significant coingestion require admission and sometimes ICU care.

A patient with uncomplicated stimulant withdrawal who is sleepy but readily arousable, maintains normal ventilation and hemodynamics, has no concerning alternative diagnosis, and progressively improves may be managed in an appropriate observation setting without mandatory inpatient admission.

Discharge

Discharge is appropriate when the patient is awake enough to function safely, has returned toward neurologic baseline, has stable vital signs and adequate ventilation, can maintain hydration, and has no untreated acute medical complication.

Before discharge, evaluate psychiatric status, particularly depression and suicidality. Persistent severe depression, psychosis, suicidal thoughts, or inability to care for oneself requires further mental-health assessment rather than simple discharge after waking.

Stimulant Use Disorder Treatment

The emergency visit should also be used to identify stimulant use disorder and offer treatment rather than simply allowing the patient to “sleep it off.”

ASAM/AAAP identifies contingency management as the behavioral intervention with the strongest evidence for stimulant use disorder and describes it as the current standard of care, often combined with approaches such as cognitive behavioral therapy or community reinforcement.

There is no single FDA-approved medication specifically for cocaine use disorder, although specialist-directed off-label pharmacotherapies may be considered in selected patients.

Prognosis

Uncomplicated stimulant crash generally has a good prognosis. Prominent sleepiness often improves over approximately 12–24 hours, although fatigue, depression, anxiety, craving, sleep disturbance, and other withdrawal symptoms may continue much longer.

Persistent deep coma or failure to improve should not simply be attributed to cocaine withdrawal. The differential diagnosis must be reopened and additional toxicologic, neurologic, infectious, or metabolic investigation performed.

Important Pitfalls

The most important pitfall is using “washed-out syndrome” as a premature explanation for coma. Modern stimulant withdrawal commonly produces hypersomnolence, but profound unresponsiveness should remain a diagnosis of exclusion.

Another major error is failing to consider fentanyl or another opioid in a patient believed to have used only cocaine. Modern polysubstance exposure is common, and opioid-associated respiratory depression requires naloxone and ventilatory support.

A positive cocaine urine test should not end the diagnostic investigation. Cocaine metabolites remain detectable beyond the period of intoxication and can coexist with stroke, infection, metabolic disease, trauma, or another overdose.

Do not assume that normal vital signs exclude serious disease. A sleeping post-binge patient may still have occult myocardial infarction, as demonstrated in historical cases of so-called washed-out syndrome.

Routine activated charcoal, gastric lavage, lumbar puncture, and broad laboratory testing are not automatically indicated simply because cocaine withdrawal is suspected. Testing and interventions should be guided by the clinical presentation.

Finally, do not overlook depression and suicide risk during the crash and withdrawal period. Modern stimulant guidelines explicitly recommend assessment for suicidality during intoxication and withdrawal.

High-Yield Toxicology Pearls

“Cocaine washed-out syndrome” is best viewed today as an acute stimulant crash/withdrawal state rather than a distinct poisoning syndrome. The expected picture is exhaustion, hypersomnolence, fatigue, dysphoria, increased appetite, and psychomotor slowing after prolonged cocaine or other stimulant use.

Many patients have marked sleepiness for approximately 12–24 hours, reflecting stimulant withdrawal and accumulated sleep deprivation. However, deep coma is not a diagnosis to accept casually.

In a cocaine user with profound depressed consciousness, always consider opioid/fentanyl coexposure, alcohol or sedatives, hypoglycemia, hypoxia/hypercapnia, stroke or intracranial hemorrhage, head injury, seizure/postictal state, infection, and metabolic disease.

Respiratory depression should prompt immediate airway assessment and naloxone when opioid exposure cannot be excluded. A positive cocaine urine screen proves recent exposure but does not prove that cocaine caused the coma.

There is no antidote for the stimulant crash and no role for routine activated charcoal, gastric lavage, dialysis, or forced elimination. Treatment is supportive: protect the airway when necessary, provide hydration and nutrition, allow restorative sleep, monitor for complications, and investigate atypical findings.

Patients should also be screened for depression, suicidality, and stimulant use disorder. Persistent psychiatric symptoms require treatment, and contingency management currently has the strongest evidence among behavioral treatments for stimulant use disorder.

The single most important modern pearl is:

Cocaine binge + sleepiness may be withdrawal; cocaine binge + coma must be proven safe before calling it “washed out.”